

CURRICULUM VITAE

Nikolaos K. Gatselis MD, PhD



Assistant Professor of Medicine

**Department of Medicine and Research Laboratory of
Internal Medicine**

University Hospital of Larissa

**University of Thessaly
Faculty of Health Sciences
Larissa Medical School**

Larissa, October 2019



Table of Contents

• PERSONAL INFORMATION	3
• EDUCATION	3
• PROFESSIONAL EXPERIENCE	3
• LICENSE TO PRACTICE MEDICINE AND SPECIALTY CERTIFICATION	5
• POSTGRADUATE TRAINING.....	5
• MEMBER OF SOCIETIES	6
• AWARDS-DISTINCTIONS.....	6
• GRANTS FOR INVESTIGATIONAL PROJECTS.....	7
• SCIENTIFIC REVIEWER FOR INTERNATIONAL MEDICAL ORGANISATIONS.....	8
• REVIEWER IN INTERNATIONAL JOURNAL	8
• MEMBER OF EDITORIAL BOARDS	9
• PARTICIPATION AS INVESTIGATOR IN INTERNATIONAL RESEARCH PROTOCOLS	10
• PARTICIPATION AS INVESTIGATOR IN GREEK RESEARCH PROTOCOLS 12	
• SPEAKER IN INTERNATIONAL CONGRESS.....	13
• ORAL PRESENTATIONS / POSTERS IN INTERNATIONAL CONGRESSES	15
• DOCTORAL THESIS	27
• PAPERS IN INTERNATIONAL MEDICAL JOURNAL	27
• PAPERS IN GREEK MEDICAL JOURNAL.....	35
• CITATION INDEX & IMPACT FACTOR (UNTIL 12/10/2019)	35
• REFEREES	36

• PERSONAL INFORMATION

First Name: Nikolaos
Family's Name: Gatselis
Father's Name: Konstantinos
Mother's Name: Maria
Place of birth: Larissa, Greece
Date of birth: December 18, 1975
Citizenship: Greek
Profession: Internist, Department of Medicine, Academic Liver Unit, University of Thessaly, Larissa Medical School.
Marital Status: Married, father of two children
Home address: 18A Safari Str, 41221 Larissa, Greece
Office address: University Hospital of Larissa, Biopolis, 41110 Larissa, Greece
Telephone: 0030-241350-2889 & 0030-6972956326 (mobile)
Fax: 0030-241350-1557
e-mail: ngatsel@med.uth.gr
Languages: Greek, English

• EDUCATION

- 2001 MD, Larissa Medical School, Faculty of Health Sciences, University of Thessaly, Greece.
- 2006 Doctoral Thesis, Larissa Medical School, Faculty of Health Sciences, University of Thessaly, Greece.
- 2011 Post Doc Research Fellow in “French National Reference Center for Viral Hepatitis B, C and delta” & “Research Team – Pathophysiology and Therapy of Chronic Viral Hepatitis”, Hospital Henri Mondor, University Paris Est, INSERM U955 (Director J-M. Pawlotsky).

• PROFESSIONAL EXPERIENCE

- Aug 2001 – now: Research Fellow & Associate, Department of Medicine & Research Lab of Internal Medicine, Larissa Medical School, Faculty of Health Sciences, University of Thessaly, Greece (Directors: Professor N. Stathakis until Aug 2008 and then Professor G.N. Dalekos).
- Aug 2001 – Nov 2001: Quarterly practice in Outpatient Clinic and Emergency Department of Medicine, Cardiology and General Surgery of Larissa Regional General Hospital.
- Nov 2001 – Nov 2002: Obligatory medical service in rural area (Health Center of Farsala, Larissa).
- Sep 2002 – Jan 2003: Trainer in First Aid National Center (Larissa).
- Jan 2003 – Mar 2004: Obligatory medical service in the Greek Army.

- May 2004 – Nov 2008: Resident in Internal Medicine, Department of Medicine & Research Laboratory of Internal Medicine, Larissa Medical School, Faculty of Health Sciences, University of Thessaly, Greece (Director: Professor N. Stathakis up to July 2008 and then Professor G.N Dalekos).
- Mar 2005 – Apr 2005: Trainer in a Post-Graduate programme of Molecular Biology in Larissa Medical School, University of Thessaly, Greece.
- Sep 2008 – Dec 2008: Advisor in Schools, Hellenic Army and Societies of parents and guardians, about sexually transmitted diseases and AIDS under the auspices of Center of Control and Prevention of Diseases of Ministry of Health and Ministry of National Education and Religious Affairs.
- Oct 2008 – May 2010: Teaching of the 3rd and 4th year medical students at the University of Thessaly, Medical School, Larissa, which involves clinical rounds and presentation of cases (as a teaching staff under labour agreement with Larissa Medical School, Faculty of Health Sciences, University of Thessaly).
- Mar 2009 – Mar 2010: Accessory Senior Registrar in Internal Medicine, Department of Medicine & Research Laboratory of Internal Medicine, Larissa Medical School, Faculty of Health Sciences, University of Thessaly (Director: Professor G.N. Dalekos).
- May 2010 – May 2011: Post Doc Research Fellow in “French National Reference Center for Viral Hepatitis B, C and delta” & “Research Team – Pathophysiology and Therapy of Chronic Viral Hepatitis”, Hospital Henri Mondor, University Paris Est, INSERM U955 (Director J-M. Pawlotsky).
- May 2011 – Feb 2013: Consultant in Internal Medicine (elect on Nov 2010), Department of Medicine, Larissa Medical School, Faculty of Health Sciences, University of Larissa (Director: Professor G.N. Dalekos).
- Feb 2013 – May 2014: Lecturer in Internal Medicine (elect on Oct 2010), Department of Medicine, Larissa Medical School, Faculty of Health Sciences, University of Larissa (Director: Professor G.N. Dalekos).
- June 2014 – now: Assistant Professor of Internal Medicine (elect on Feb 2014), Department of Medicine, Larissa Medical

School, Faculty of Health Sciences, University of Larissa (Director: Professor G.N. Dalekos).

- **LICENSE TO PRACTICE MEDICINE AND SPECIALTY CERTIFICATION**

- 2001 Certificate of Registration, as a Medical Practitioner (Ministry of Health, Athens, Greece).
- 2009 Certificate of Internal Medicine

Registration/Medical License number: 5390/24-07-2001

- **POSTGRADUATE TRAINING**

- 2002 **Laboratory of Immunology in Clinical Practice**, Department of Medicine, Larissa Medical School, University of Thessaly, Greece
- 2003 **Diagnostic Immunology and Histocompatibility**, Larissa Medical School, University of Thessaly, Greece.
- 2004 **Statistical data analysis in clinical trials or experimental studies using statistical packages**, Laboratory of Biomathematics, Larissa Medical School, University of Thessaly, Greece.
- 2007-2008 **Antibiotics: Mechanism of action – Resistant – Evidence based treatment**, Institute of Biomedical Research and Technology, Larissa, Greece.
- 2008 **Acid-Base Balance and Electrolytes Disorders**, Department of Medicine and Research Laboratory of Internal Medicine, Larissa Medical School, University of Thessaly and 2nd Department of Medicine, Ioannina Medical School, Greece.
- 2008 **Liver transplantation and acute liver failure**, EASL Clinical School of Hepatology (Course 10), London, UK.
- 2008 **Information program in schools, the army and the parents' associations on Sexually Transmitted Diseases and AIDS**, Hellenic Center for Diseases Control and Prevention and General Secretariat for Lifelong Learning Adult Education.
- 2008-2015 **1st, 2nd, 3rd, 4th, 5th, 6th, 7th Postgraduate Educational Program**, Department of Medicine and Research Laboratory of Internal Medicine, Larissa Medical School, University of Thessaly in collaboration with Institute of Internal Medicine and Hepatology.
- 2008-2009 **2nd Clinical School of Hepatology**, Hellenic Association for the Study of the Liver.
- 2009 **Training in ultrasound liver elastography (Fibroscan®)**.
- 2009 **Autoimmune Hepatitis, PBC and PSC**, EASL Clinical School of Hepatology (Course 13), Hannover, Germany.
- 2009 **Keeping the patient with End-stage Cirrhosis Alive**, AASLD Postgraduate Course, Boston, MA, USA.
- 2010 **Management of Acute Clinical Conditions in Hepatology**, EASL Postgraduate course, Vienna, Austria.
- 2011 **Cholestatic diseases of the liver and bile ducts**, EASL Postgraduate Course, Berlin, Germany.

- 2011 **Cirrhosis: Current Challenges and Future Directions**, AASLD Postgraduate Course, San Francisco, CA, USA.
- 2012 **Personalized Medicine and the Practice of Hepatology**, AASLD Postgraduate Course, Boston, MA, USA.
- 2013 **Transplantation and the Liver**, EASL Postgraduate Course, Amsterdam, the Netherlands.
- 2014 **Viral Hepatitis**, EASL Postgraduate Course, London, UK.
- 2014 **Clinical Implications of Inflammation and Immunity in Acute and Chronic Liver Disease: Advances in Diagnosis, Treatment and Clinical Practice**, AASLD Postgraduate Course, Boston, MA.
- 2015 **Metabolic Liver Disease**, EASL Postgraduate Course, Vienna, Austria.
- 2015 **Managing Liver Disease – From the Clinic to the Community**, AASLD Postgraduate Course, San Francisco, CA, USA.
- 2015 **Autophagy in the Liver**, AASLD Basic Science Symposium, San Francisco, CA, USA.
- 2016 **Challenges in the Management of Common Liver Diseases**. AASLD Postgraduate Course, Boston, MA, USA.
- 2017 **A multidisciplinary approach to patients with liver disease**. EASL Postgraduate Course, Amsterdam, The Netherlands.
- 2017 **21st Century Hepatology: Translating discoveries into practice**. AASLD Postgraduate course, Washington, DC, USA.
- 2018 **Viral Hepatitis**. EASL Postgraduate Course, Paris, France.
- 2019 **End Stage Liver Disease**. EASL Postgraduate Course, Vienna, Austria

• MEMBER OF SOCIETIES

- Hellenic Society of Internal Medicine of Northern Greece (Greek)
- Hellenic Association for the Study of the Liver (Greek)
- European Association for the Study of the Liver
- Hellenic Society of Chemotherapy (Greek)

• AWARDS-DISTINCTIONS

1. **Four scholarships** by the Institution of State Scholarships (Greece), 1993, 1998, 1999 and 2001.
2. **First Award** of Olympic Medical Knowledge, 7th Congress of Hellenic Society of Medical Students, Larissa April 27-29, 2001.
3. **First Award** in poster session entitled: *“Presence of G209A mutation in a-SYNUCLEIN gene in Greek families with Parkinson disease”* presented in 7th Congress of Hellenic Society of Medical Students, Larissa April 27-29, 2001.
4. Attendance at the **EASL Clinical School of Hepatology Course 10 – Liver Transplantation and Acute Liver Failure**, London, June 20-22, 2008, after being selected by the **EASL Scientific Committee**.
5. Attendance at the **EASL Clinical School of Hepatology Course 13 – Autoimmune Hepatitis, PBC and PSC**, Hanover, December 3-6, 2009, after being selected by the **EASL Scientific Committee**.

6. **Travel bursary for Young Investigators EASL (European Association for the Study of the Liver) Scientific Committee** for the attendance of 46th Annual Meeting of the European Association for the Study of the Liver, Berlin, April 2011 and presentation of research study entitled “**Hepatitis Delta Virus RNA Detection and Quantification: Issues with standardization and needs for clinical practice**”.
7. **Award** for best oral presentation in the 10th Congress of the European Federation of Internal Medicine, entitled «**Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of patients**» presented in Athens, 5-8 October 2011.
8. **Second Award** by the Hellenic Association for the Study of the Liver entitled: “**Decreased production of hepcidin in patients with autoimmune liver diseases**” presented in the 13th Panhellenic Congress of Hepatology, Rhodes, May 9-12, 2013.
9. **Hepatitis Delta International Network / EASL Registry Grant** (Project Manager Prof. Dr. Heiner Wedemeyer) (July 2014).
10. **1st Award** for best oral presentation in the 1st Panhellenic Congress on Continuing Education in Internal Medicine, Internal Medicine Society of the Northern Greece – Hellenic Professional Union of Internists, entitled “**Long term outcome of patients with AIH treated with mycophenolate mofetil as first line therapy**” presented in Thessaloniki, 26-28 February 2015.
11. **3rd Award** for best oral presentation in the 14th Panhellenic Liver Congress, Hellenic Association for the Study of the Liver, entitled “**Decreased serum activity of DNase-1 in patients with autoimmune liver diseases**” presented in Kos, 7-10 May 2015.
12. **2nd Award** for best poster in the 14th Panhellenic Liver Congress, Hellenic Association for the Study of the Liver, entitled “**Treatment of portal vein thrombosis in cirrhotic patients**” presented in Kos, 7-10 May 2015.
13. **1st Award** for best oral presentation in the 15th Panhellenic Liver Congress, Hellenic Association for the Study of The Liver, entitled “**The significance of IP10 in patients with HBeAg-negative chronic hepatitis B who discontinue long term treatment with entecavir or tenofovir: DARING-B, a prospective study**”.

• GRANTS FOR INVESTIGATIONAL PROJECTS

1. My thesis was partially granted by the Research Committee of the University of Thessaly. The title of the investigational project was: “Non-organ specific autoantibodies and autoantibodies related with autoimmune liver diseases in patients with chronic hepatitis C virus infection treated with classical induction therapies with interferon- α and ribavirin”. (Scientific supervisor of the project: Professor G.N. Dalekos).
2. Grant from ROCHE company for the study entitled: “The role of interleukine-28B polymorphism (SNP rs12979860) in chronic hepatitis B natural history and response to treatment with interferon- α ».

3. Grant from GILEAD company (15000 euro) for the study entitled: «The role of polymorphism in the gene of programmed cell death 1.3a (PD-1.3A) in the natural history and response to treatment of chronic hepatitis B and C (2014).
4. Grant from the «Hepatitis Delta International Network / EASL Registry Grant» (500 euro) (2014).
5. Grant for Hellenic Association for the Study of the Liver for the study entitled: “Metabolomics in Autoimmune Liver Diseases” (15000 euro) (2015).

- **SCIENTIFIC REVIEWER FOR INTERNATIONAL MEDICAL ORGANISATIONS**

1. Scientific reviewer of the **Rational Pharmacotherapy program of ZonMw (The Netherlands Organisation for Health Research and Development)** for the study “Towards steroid-free treatment of autoimmune hepatitis (Dossier number: 80-84800-98-83028), Prof. dr. G. Bouma). [April 2014].

- **REVIEWER IN INTERNATIONAL JOURNAL**

1. Molecular and Cellular Endocrinology
2. Journal of Medical Virology
3. Alimentary Pharmacology & Therapeutics
4. Journal of Gastroenterology and Hepatology
5. Journal of Medical Case Reports
6. European Journal of Pediatric Neurology
7. Digestive and Liver Disease
8. Journal of Forensic Medicine
9. BMJ Infectious Diseases
10. Liver International
11. BMC Research Notes
12. World Journal of Hepatology
13. World Journal of Gastroenterology
14. World Journal of Radiology
15. Current Bionanotechnology
16. Annals of Gastroenterology
17. Journal of Pediatric Intensive Care
18. World Journal of Gastrointestinal Surgery
19. Journal of International Medical Research
20. World Journal of Gastrointestinal Pharmacology and Therapeutics
21. Annals of Hepatology
22. Postgraduate Medicine

23. Mathews Journal of Gastroenterology and Hepatology
24. Therapeutic Advances in Gastroenterology
25. Case Reports in Hepatology
26. Mediterranean Journal of Hematology and Infectious Diseases
27. BMJ Case Reports
28. World Journal of Transplantation
29. Journal of Case Reports and Imaging
30. Drugs and Therapy Perspectives
31. Biomedicine and Pharmacotherapy
32. European Journal of Clinical Microbiology & Infectious Diseases
33. Health Science Reports
34. BMJ Open
35. BMJ Open Gastroenterology
36. Northern Clinics of Istanbul
37. World Journal of Clinical Oncology
38. Case Reports in Infectious Diseases
39. Journal of Laboratory Medicine
40. Viruses
41. PLoS One
42. Cancers
43. Hepatology Research
44. Digestive Diseases and Sciences

• **MEMBER OF EDITORIAL BOARDS**

1. World Journal of Hepatology (2014-2017)
2. Mathews Journal of Gastroenterology and Hepatology (2016 – now).
3. Annals of Clinical Case Reports – Internal Medicine Case Reports (2016 – now)
4. SM Journal of Case Reports (2016 – now)
5. Journal of Case Reports and Imaging (2016 – now)
6. Journal of Immunological Diseases, Disorders and their Prevention (2016 – now)
7. Journal of Drug Metabolism & Toxicology (2016-now)
8. World Journal of Gastroenterology (2016-now)
9. Journal of Clinical Research & Case Reports (2017-now)
10. Northern Clinic of Istanbul (2019-now)
11. American Journal of Internal Medicine (2019-now)

• PARTICIPATION AS INVESTIGATOR IN INTERNATIONAL RESEARCH PROTOCOLS

1. A multicenter, double blinded study in patients with chronic hepatitis C who are non-responders to prior peginterferon-a or peginterferon-a + ribavirin therapy comparing treatment with thymosin a1 + peginterferon-a-2a plus ribavirin with peginterferon-a-2a + ribavirin + placebo (Coordinator: Professor M. Rizzetto) (2006-2008) (This study was audited by independent authorities with excellent conclusions).
2. A multicenter, double blinded study on Tenofovir vs Adefovir in the treatment of naïve patients with chronic anti-HBe positive hepatitis B (2006 - 2016). (We have been audited for this study by American authorities funded by Gilead with excellent conclusions)
3. A multicenter, Phase 3b, randomized, double-blind, double-dummy study, evaluating the antiviral efficacy, safety, and tolerability of Tenofovir Disoproxil Fumarate monotherapy versus Emtricitabine plus Tenofovir DF fixed-dose combination therapy in subjects with chronic hepatitis B who are resistant to lamivudine (2009-2010).
4. «Hepatitis B sample collection study» (BB-ID-034) (2010-2014)
5. “Multicenter, Open-Label, study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis (VX-950HEP3002)” (2011 - 2014).
6. “A phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs telaprevir, both in combination with Peg-IFN α -2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFN α and ribavirin therapy” (TMC435HPC3001) (2012-2013).
7. “Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C” (MV25599) (2012-2015).
8. “An international, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics” (MV25600) (2012-2014).
9. “Use of boceprevir in addition to standard Pegylated Interferon alpha and Ribavirin regimen in genotype 1 Chronic Hepatitis C treatment-experienced patients in the Greek routine clinical practice” (2013-2015).
10. Member of Hepatitis Delta International Network (a group dedicated to the study of the hepatitis delta virus since 2007). (2012-now)
11. “OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib” (BAY 43-9006, Sorafenib / study identifier: 16560/NX 1301) (2013-2016).
12. “A phase IV, blood sample collection study for exploratory evaluation of the association of single nucleotide polymorphisms with treatment responses from

subjects with HBe-Ag positive or negative chronic hepatitis B, who received therapy for hepatitis B with peginterferon alpha-2a 40kD ± Nucleos(t)ide analogue (Sponsor: F-Hoffmann-La Roche Ltd) (2014-2015).

13. An international, multicenter, prospective, observational study to assess the epidemiological, humanitarian and economic outcomes of treatment of chronic hepatitis C (Sponsor: ABBVIE) (2014-2015).
14. “A Randomized, Multi-Center, Phase 2 Study to Evaluate Safety and Efficacy of Subcutaneous Injections of RG-101 in Combination with Oral Agents in Treatment Na.ve, Genotype 1 and 4, Chronic Hepatitis C Patients” (Sponsor Regulus Therapeutics Inc.) (2015-2017) (This study was audited by independent authorities with excellent conclusions).
15. “A multi-center, parallel group, open-label, phase 2 study to evaluate the efficacy and safety of a single subcutaneous injection of RG-101 combined with oral GSK2878175 taken once daily for 6, 9, or 12 weeks in treatment naïve, genotype 1 and 3, chronic hepatitis C patients (RG101-04)” (2016-now)
16. “Moving from biochemically early to advanced PBC: Are there any prognostic factors? (Global PBC Study Group) (2016-now)
17. “Assessment of IAIHG criteria for PSC-AIH overlap (International PSC Study Group)” (2016-now)
18. “An observational long-term safety and efficacy follow-up study of subjects who have previously received RG-101 (RG101-05) (2016-now)
19. “Diagnostic performance of Fibrometer® in the assessment of liver fibrosis alone or in combination with Fibroscan®” (ECHOSENS) (2016-now)
20. “AIH and NAFLD/NASH: i) Do all NASH patients have truly only NASH? ii) NAFLD/NASH in AIH: important player or innocent bystander?” (IAIHG) (2016-now)
21. “Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis NN9931-4296” (2017-now)
22. “Phase IIA exploratory study of oral Milciclib Maleate in patients with Unresectable or Metastatic Hepatocellular Carcinoma” (2017-now)
23. “A European, observational, three-year cohort comparative study on the safety of the fixed-dose combination pravastatin 40mg/fenofibrate 160 mg (Pravafenix®) versus statin alone in real clinical practice. (POSE: Pravafenix® Observational Study in Europe)” (2017-now)
24. “A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase (GSN000300)” (2017-2019)
25. “EU-Wide Cross-sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care DA VINCI (20150333)” (2018-2019)
26. “Long-term outcome and risk stratification in autoimmune hepatitis - an international, multicenter retrospective observational study” (2018-now)

27. “A prospective, randomized, open-label, comparative study to assess the efficacy, safety and tolerability of aztreonam=avibactam (ATM-AVI) and best available therapy for the treatment of serious infections due to multi-drug resistant gram-negative bacteria producing metallo-b-lactamase (MBL)” (2019-now)
28. “A Phase 2, Double-Blind, Randomized, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid, Administered Alone or in Combination with Bezafibrate, in Subjects with Primary Biliary Cholangitis who had an Inadequate Response or who were Unable to Tolerate Ursodeoxycholic Acid (INTERCEPT 747-213)” (2019-now)
29. “Novel technologies for surveillance and characterization of Extended-spectrum β -lactamase and Carbapenemase producing Enterobacteriaceae, in humans and animals” (2018-now)
30. “Surveillance strategies for HB malignancy (International PSC Study Group)” (2018-now)
31. “Screening and management of dominant strictures in PSC: a multicenter cohort analysis (International PSC Study Group)” (2018-now)
32. “Biomarkers for liver inflammation and their impact on the prognosis of PSC - Particularly, the impact of serum IgG and ALT levels on disease progression will be analysed, then impact of immunosuppressive treatment (International PSC Study Group)” (2018-now)
33. “A 52-week, placebo-controlled, randomised, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis and an inadequate response to or an intolerance to UDCA (CB8025-31735)” (2019-now)

ICH GCP Training:

Global Health Training Centre, Certificate Number 469751, 20 August 2018

• PARTICIPATION AS INVESTIGATOR IN GREEK RESEARCH PROTOCOLS

1. Multicenter (23 centers) non-interventional study Phase IV: Prognostic factors of long term response to treatment with pegylated interferon alpha-2a in HBeAg negative chronic hepatitis B patients (PERSEAS) (2009-2012).
2. Multicenter study: Study of immunological responses in patients with sepsis, severe sepsis and septic shock. Hellenic Society of Chemotherapy. (2009-now)
3. Prospective, multicenter, non-interventional epidemiological study of infectious endocarditis in Greece. Hellenic Society of Chemotherapy. (2011-now)
4. “Study of polymorphisms of Toll-like Receptor (TLR)-4 and tumor necrosis factor- α (TNF- α) in patients with brucellosis. 4th Department of Internal Medicine, University Hospital ATTIKON, School of Medicine National and Kapodistrian University of Athens. (2011-now)

5. “In vitro study for telavancin activity against staphylococcal species and correlation with phenotypes of resistance in Greece”. Department of Microbiology, Larissa Medical School, University of Thessaly, 4th Department of Internal Medicine, University Hospital ATTIKON, School of Medicine National and Kapodistrian University of Athens. (2011).
6. Research project entitled «Mechanisms of signal transduction and gene expression in hepatocellular carcinoma» (THALIS). Department of Biology, Aristotle University of Thessaloniki. (2012-2016)
7. Multicenter retrospective/prospective non-interventional study: «Use of boceprevir in addition to standard Pegylated Interferon alpha and Ribavirin regimen to genotype 1 Chronic Hepatitis C treatment-experienced patients in the Greek routine clinical practice». (2013-2015).
8. “Comparison of leishmania species in human and dogs and their geographic distribution in Thessaly” (2015-now)
9. “Metabolomic profile in patients with autoimmune liver diseases with NMR spectroscopy” (2015-now)
10. “DARING-B: Discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) patients: a prospective Greek study (GILEAD)” (2015-2017)
11. Spontaneous Bacterial Peritonitis in cirrhosis: a Prospective Multicenter Study of Clinical, Microbiological characteristics and Predictors of 6 months Survival. (2015-now)
12. Everyday clinical practice data about the activity of paritaprevir/ritonavir, ombitasvir/Dasabuvir ± ribavirin in patients with chronic hepatitis C - Observation Study in Greece (OPAL-ABBVIE) (2016-2017)
13. “Autoimmune Hepatitis Registry” (2016-now)
14. “Open label randomized study for the efficacy and safety of mycophenolate mofetil comparing to azathioprine for the induction of on-treatment remission and remission after treatment discontinuation in treatment naïve patients with autoimmune hepatitis” (2016-now).
15. “Natural History – Portal Vein Thrombosis Study” (2017-2019)
16. “Tenofovir alafenamide in chronic hepatitis B: A Hellenic multicenter ReAl-life Clinical Study (HERACLIS-TAF)” (2019-now)

• SPEAKER IN INTERNATIONAL CONGRESS

1. Scientific meetings at Institut Mondor de Recherche Biomédicale, INSERM U955 (EQ.18), Département de Virologie Moléculaire et Immunité Physiopathologie et Thérapeutique des Hépatites Virales Chroniques (Pr. J.-M. Pawlotsky), Creteil, Paris, France: “**HDV Quantification Issues**”, Paris, 16 November 2011.
2. 46th Annual Meeting of the European Association for the Study of the Liver - Berlin 2011. Early Morning Workshop: What’s new in delta virus infection? (Chairpersons: Prof. Erhardt & Prof. Yalcin), **Saturday, April 2, 2011**. Invited speaker to present my abstract entitled “**Hepatitis Delta Virus RNA Detection**”

and Quantification: Issues with standardization and needs for clinical practice”.

3. 48th Annual Meeting of the European Association for the Study of the Liver - Amsterdam 2013. 5th Hepatitis Delta International Network (HDIN) meeting (Chairpersons: Prof. P. Manns & Prof. H. Wedemeyer). **Wednesday, April 24, 2013**. Oral speech: **“Chronic Hepatitis D virus infection in Greece: Experience from a single centre and data from the Hellenic Center for Disease Control and Prevention (HCDCP)”**.
4. 8th Larissa International Congress of Internal Medicine – Satellite Symposium sponsored by Bristol-Myers Squibb: Chronic Hepatitis C Treatment Management: From Clinical Trials to Clinical Practice! Larissa, **March 19, 2016**. **“Chronic Hepatitis C: Local & Global Treatment Guidelines”**.
5. European Association for the Study of the Liver – The International Liver Congress 2016 – Barcelona, Spain, **April 13-17, 2016**. International Autoimmune Hepatitis Group meeting (Chairperson: Prof. D. Vergani). Oral speech: **“AIH in NASH vs Steatosis in AIH: a follow up of the proposal in San Francisco”**.
6. American Association for the Study of Liver Diseases – The Liver Meeting 2016 – Boston, USA, **November 11-15, 2016**. Global PBC Study Group meeting (Chairpersons: Prof. G. Hirschfield & Prof. B. Hansen). Oral speech: **“Moving from biochemically early to advanced PBC: are there any prognostic factors?”**
7. American Association for the Study of Liver Diseases – The Liver Meeting 2016 – Boston, USA, **November 11-15, 2016**. International Autoimmune Hepatitis Group meeting (Chairperson: Prof. D. Vergani). Oral speech: **“Antimitochondrial antibodies in AIH”**.
8. Instructor in European School of Internal Medicine (an educational initiative of the European Federation of Internal Medicine), Riga, Latvia, **February 5-11, 2017**. Oral Speech: **Deranged liver biochemistry in asymptomatic individuals: What to do?**
9. K. Zachou, P. Arvaniti, N.K. Gatselis, K. Azariadi, G.K. Koukoulis, G.N. Dalekos. **Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis (AS-AIH) and the need for liver transplantation (LT)**. The International Liver Congress 2017. European Association for the Study of the Liver. Amsterdam, The Netherlands, April 19-23, 2017. (the study was selected for oral presentation during poster tour).
10. 11th International Forum for Medical Students and Junior Doctors. Larissa, Greece, May 12, 2017. **“Unmasking autoimmune hepatitis diagnosis: A hard issue?”**
11. Instructor in Stroke Summer School of the European Stroke Organisation, Larissa, Greece, **September 10-15, 2017**. Oral Lecture: **“CNS vasculitis and other rare causes of stroke”**.
12. European Association for the Study of the Liver – The International Liver Congress 2019 – Vienna, Austria, **April 10-14, 2019**. International Autoimmune Hepatitis Group meeting (Chairperson: R. Liberal, Y. de Boer). Oral speech: **“Antimitochondrial autoantibodies in AIH”**.

13. American Association for the Study of Liver Diseases – The Liver Meeting 2019 – Boston, USA, **November 8-12, 2019**. International Autoimmune Hepatitis Group meeting (Chairs: Y. de Boer, R. Liberal). Oral speech: “**Antimitochondrial antibodies positivity in AIH**”.
14. American Association for the Study of Liver Diseases – The Liver Meeting 2019 – Boston, USA, **November 8-12, 2019**. Global PBC Study Group meeting (Chairs: B. Hansen, M. Mayo). Oral speech: “**Prevalence and significance of extrahepatic autoimmune diseases in PBC**”.
15. American Association for the Study of Liver Diseases – The Liver Meeting 2019 – Boston, USA, **November 8-12, 2019**. Global PBC Study Group meeting (Chairs: B. Hansen, M. Mayo). Oral speech: “**The significance of IgM in PBC patients**”.

(*84 additional lectures in Greek congresses)

• ORAL PRESENTATIONS / POSTERS IN INTERNATIONAL CONGRESSES

1. K. Zachou, Ch. Liaskos, D. Christodoulou, M. Kardasi, G. Papadamou, **N. Gatselis**, F. Gerovasilis, E. Tsianos, G. Dalekos. Anti-cardiolipin antibodies (anti-CL) in patients with hepatitis C virus (HCV) infection are independent of beta2-glycoprotein I (b2GPI) co-factor of features of antiphospholipid syndrome (APS). **J Hepatol** 2002; 36 (Suppl 1) :139
2. C. Liaskos, T.A. Zografos, E. Togousidis, K. Zachou, **N. Gatselis**, E. Rigopoulou, A. Germenis, G.N. Dalekos. Alterations of leptin levels during IFN-alpha treatment in patients with chronic viral hepatitis B and C: Evidence of an IFN-alpha-mediated suppression production. **Hepatology** 2005; 42 (Suppl 4):673A.
3. D.P. Bogdanos, C. Liaskos, G.L. Norman, M. Horner, D. Murphy, **N. Gatselis**, E.I. Rigopoulou, H. Smith, D. Vergani, G.N. Dalekos. Interferon-alpha unmasks a novel golgi-like immunofluorescence pattern specifically present in patients with chronic hepatitis C virus (HCV) infection. **Autoimmunity Reviews** 2006; ISSN 1568-9972;p.257-258.
4. C. Liaskos, D.P. Bogdanos, **N. Gatselis**, M. Homer, Z. Shums, D. Murphy, E.I. Rigopoulou, H. Smith, D. Vergani, G.L. Norman, G.N. Dalekos. Chronic hepatitis C is characterized by an interferon-alpha induced novel autoantibody giving a crescent pattern by indirect immunofluorescence. **J Hepatol** 2007; 46 (Suppl 1): S172.
5. E. Kapsalaki, A. Balatsouka, A. Vassiou, **N. Gatselis**, G. Dalekos, I. Fezoulidis. The role of MRI in the early diagnosis and follow-up of patients with spondylodiscitis. **Neuroradiology** 2007; 49 (Suppl 2).
6. S. Gabeta, G.L. Norman, **N. Gatselis**, C. Liaskos, P.A. Papamichalis, A. Garagounis, K. Zachou, E.I. Rigopoulou and G.N. Dalekos. IgA isotype specific anti-b2GPI antibodies in patients with autoimmune liver diseases. **J Hepatol** 2008; 48 (Suppl 2): 330.

7. S. Barbanis, F. Karasavvidou, **N. Gatselis**, D. Pappa, R. Papamichali, G. Dalekos. A unique case of Henoch-Schonlein purpura in a very old woman. *Histopathology* 2008; 53: 387.
8. M. Mytilinaiou, W. Meyer, A. Janssen, P. Pavlides, C. Probst, **N.K. Gatselis**, L. Komorowski, W. Schlumberger, D. Vergani, D.P. Bogdanos. Diagnostic and clinical application of a new live immunoassay that simultaneously detects the multiple nuclear dot specific antigens in primary biliary cirrhosis. *J Hepatol* 2009; 50 (Suppl 1): 249.
9. **N. Gatselis**, F. Le Gal, I. Mederacke, A. Soulier, B. Bremer, C. Rodriguez, S. Chevaliez, H. Wedemeyer, E. Gordien, J-M. Pawlotsky. Hepatitis Delta Virus RNA detection and quantification: Issues with standardization and needs for clinical practice. *J Hepatol* 2011; 54 (Suppl 1): 148
10. K. Zachou, **N. Gatselis**, G. Papadamou, E.I. Rigopoulou, G.N. Dalekos. Mycophenolate for autoimmune hepatitis treatment: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment naïve patients. *J Hepatol* 2011; 54 (Suppl 1): 518
11. **N. Gatselis**, K. Zachou, G.L. Norman, S. Gabeta, A. Stefos, G.N. Dalekos. Serial analysis of autoantibodies in patients with primary biliary cirrhosis. *Eur J Intern Med* 2011; 22 (Suppl 1): 101.
12. K. Zachou, **N. Gatselis**, G. Papadamou, E.I. Rigopoulou, G.N. Dalekos. Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of patients *Eur J Intern Med* 2011; 22 (Suppl 1): 24
13. **N. Gatselis**, K. Zachou, G. Tzelas, S. Gabeta, G.K. Koukoulis, A. Germenis, G.N. Dalekos. Clinical significance of deamidated gliadin peptide antibodies in patients with chronic liver diseases. *Eur J Intern Med* 2011; 22 (Suppl 1): 34.
14. **N.K. Gatselis**, K. Zachou, G.L. Norman, G. Tzelas, S. Gabeta, M. Speletas, G.K. Koukoulis, G.N. Dalekos. IgA antibodies against deamidated gliadin peptides and tissue-transglutaminase in patients with chronic liver diseases. *J Hepatol* 2012; 56 (Suppl 2): S383
15. **N.K. Gatselis**, K. Zachou, G.L. Norman, S. Gabeta, G.K. Koukoulis, G.N. Dalekos. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. *J Hepatol* 2012; 56 (Suppl 2): S368-369
16. Lyberopoulou, G. Chachami, **N.K. Gatselis**, P. Eliades, E. Paraskeva, K. Zachou, A Mamalaki, G.N. Dalekos, G. Simos. Determination and significance of serum hepcidin and liver hepcidin mRNA levels in patients with hepatopathies. *FEBS Journal* 2012; 279 (Suppl 1): 52-576.
17. **N.K. Gatselis**, A. Soulier, S. Chevaliez, K. Patel, A.J. Muir, J.-M. Pawlotsky. Utility of serum samples for IL28B genotyping: A valuable source of genomic DNA. *J Hepatol* 2013; 58 (Suppl 1): S:187.
18. G. Papatheodoridis, **N. Gatselis**, I. Goulis, S. Karatapanis, M. Deutsch, K. Mimidis, C. Drakoulis, E. Akriviadis, G.N. Dalekos. IL28B polymorphisms as predictors of response to peginterferon-alfa-2a in HBeAg-negative chronic hepatitis B. *Hepatology* 2013; 58 (Suppl1).

19. K. Zachou, **N.K. Gatselis**, S. Gabeta, A.I. Saitis, G. Papadamou, E.I. Rigopoulou, G.N. Dalekos. Autoimmune hepatitis natural history: a single Greek center experience focused on long-term effect of mycophenolate mofetil as first line treatment. *Hepatology* 2013; 58 (Suppl1).
20. G.V. Papatheodoridis, G.N. Dalekos, C. Yurdaydin, I. Goulis, P. Arends, M. Buti, V. Sypsa, S. Manolakopoulos, G. Mangia, **N. Gatselis**, O. Keskin, S. Savvidou, B.E. Hansen, C. Papaioannou, K. Galanis, R. Idilman, M. Colombo, R. Esteban, H.L. Janssen, P. Labertico. Risk and risk factors of Hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF). *Hepatology* 2013; 58 (Suppl1).
21. T.J. Weismuller, J.A. Talwalkar, C.Y. Ponsioen, D.N. Gotthardt, H.-U. Marschall, S. Naess, K. Holm, R.K. Weersma, K.N. Lazaridis, J. Fevery, P.J. Trivedi, C. Schramm, O. Chazouilleres, T. Muller, M. Farkkila, S. Almer, S. Pereira, A.L. Mason, A. Floreani, P. Milkiewicz, H. Harley, A. Pares, L. de Vries, C. Manser, **N. Gatselis**, C. Berg, H. Lenzen, M. Benito de Valle M. Imam, G. Kirchner, P. de Leuw, V. Zimmer, L. Fabris, F. Braun, G.M. Hirschfield, M. Marzioni, B.D. Juran C.P. Strassburg^[SEP]U. Beuers, M.P. Manns, E. Schrumph, T.H. Karlsen, A. Bergquist, K.M. Boberg, International PSC Study Group. Primary Sclerosing Cholangitis from a global perspective – A multicenter, retrospective, observational PSC study group. *J Hepatol* 2014.
22. K. Zachou, S. Gabeta, **N.K. Gatselis**, K. Oikonomou, I. Goulis, M.N. Manoussakis, Y. Renaudineau, D.P. Bogdanos, G.N. Dalekos. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. *J Hepatol* 2014.
23. G.V. Papatheodoridis, G. Dalekos, V. Sypsa, C. Yurdaydin,^[SEP]M. Buti, J. Goulis, P. Arends, S. Manolakopoulos, G. Mangia, **N. Gatselis**, O. Keskin, S. Savvidou, B.E. Hansen, C. Papaioannou, K. Galanis, R. Idilman, M. Colombo, R. Esteban, H.L.A. Janssen, P. Lampertico. PAGE-B: Risk score for Hepatocellular Carcinoma development in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 2014.
24. **N. Gatselis**, K. Zachou, A.I. Saitis, E. Spyrou, G.K. Koukoulis, G.N. Dalekos. Geoepidemiology of primary biliary cirrhosis in Central Greece. *Hepatology* 2014; 60 (Suppl1), 358A.
25. **N. Gatselis**, A. Lyberopoulou, K. Zachou, G. Chachami, P. Eliades, S. Gabeta, E. Paraskeva, A. Mamalaki, G.K. Koukoulis, G. Simos, G.N. Dalekos. Down-regulation of hepcidin production in patients with autoimmune liver diseases. *Hepatology* 2014; 60 (Suppl1), 365A.
26. S. Gabeta, K. Zachou, Z. Shums, **N. Gatselis**, G.K. Koukoulis, G.L. Norman, G.N. Dalekos. Cartilage oligomeric matrix protein (COMP) serum levels: a new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. *Hepatology* 2014; 60 (Suppl1), 415A.
27. G.L. Norman, **N. Gatselis**, Z. Shums, C. Liaskos, D.P. Bogdanos, G.K. Koukoulis, G.N. Dalekos. Cartilage oligomeric matrix protein (COMP): A novel non-invasive marker for assessing liver cirrhosis and risk of progression to hepatocellular carcinoma. *Hepatology* 2014; 60 (Suppl1), 801A.

28. G.V. Papatheodoridis, G.N. Dalekos, V. Sypsa, C. Yurdaydin, M. Buti, I. Goulis, H. Chi, S. Manolakopoulos, G. Mangia, **N. Gatselis**, O. Keskin, S. Savvidou, B.E. Hansen, J. Vlachogiannakos, K. Galanis, R. Idilman, M. Colombo, R. Esteban, H.L. Janssen, P. Lampertico. Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in Caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF). *Hepatology* 2014; 60 (Suppl1), 316A.
29. **N.K. Gatselis**, A.G. Vakrakou, K. Zachou, T. Androutsakos, K. Azariadi, G. Hatzis, M.N. Manoussakis, G.N. Dalekos. Decreased Serum DNase1 activity in patients with autoimmune liver diseases. 7th International Congress of Internal Medicine of Central Greece. Larissa, Greece, March 19-21, 2015.
30. K. Zachou, **N. Gatselis**, S. Gabeta, A. Saitis, E.I. Rigopoulou, G.K. Koukoulis, G.N. Dalekos. Long-term outcome of patients with autoimmune hepatitis receiving mycophenolate mofetil (MMF) as first line treatment. 7th International Congress of Internal Medicine of Central Greece. Larissa, Greece, March 19-21, 2015.
31. **N.K. Gatselis**, K. Zachou, E.I. Rigopoulou, G. Papadamou, K. Galanis, G.N. Dalekos. Telbivudine for the treatment of chronic hepatitis B: A case series. 7th International Congress of Internal Medicine of Central Greece. Larissa, Greece, March 19-21, 2015.
32. **N.K. Gatselis**, G.L. Norman, K. Zachou, Z. Shums, A. Saitis, S. Gabeta, G.N. Dalekos. Golgi Protein (GP73): A new non-invasive biomarker for assessing liver fibrosis and risk of progression to hepatocellular carcinoma. 7th International Congress of Internal Medicine of Central Greece. Larissa, Greece, March 19-21, 2015.
33. S. Hardtke, Z. Abbas, S. Hamid, E. Ceausu, G.N. Dalekos, G. Niro, G. Corti, L.M. Pinheiro Borzacov, R. Parana, ^[1]**N.K. Gatselis**, A. Motoc, P. Ingiliz, M. Mucic, A. Wranke, ^[1]M. Wobse, C. Yurdaydin, M.P. Manns, H. Wedemeyer, ^[1]on behalf of The Hepatitis Delta International Network. Global epidemiology of hepatitis delta: First data from the Hepatitis Delta International Network. 50th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, April 22-26, 2015.
34. G. Papatheodoridis, G. Dalekos, C. Yurdaydin, M. Buti, V. Sypsa, J. Goulis, J.L. Calleja, H. Chi, S. Manolakopoulos, G. Mangia, **N. Gatselis**, O. Keskin, S. Savvidou, J. De La Revilla, B.E. Hansen, I. Vlachogiannakos, K. Galanis, R. Idilman, M. Colombo, R. Esteban, H.L. Janssen, P. Lampertico. Excellent 5-year survival in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC). 50th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, April 22-26, 2015. [oral presentation].
35. K. Zachou, **N. Gatselis**, S. Gabeta, A. Saitis, G. Koukoulis, G.N. Dalekos. Long-term outcome with autoimmune hepatitis receiving mycophenolate mofetil (MMF) as first line treatment. 50th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, April 22-26, 2015.
36. **N.K. Gatselis**, A.G. Vakrakou, K. Zachou, T. Androutsakos, K. Azariadi, G. Hatzis, M.N. Manoussakis, G.N. Dalekos. Decreased serum DNase1 activity in

patients with autoimmune liver diseases. 50th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, April 22-26, 2015.

37. E. Giannitsioti, S. Georgiadou, **N. Gatselis**, K. Makaritsis, G. Damoraki, M. Pavlaki, M. Mouktaroudi, G. Dalekos, E. Giamarellos- Bourboulis. TLR4 single nucleotide polymorphisms in Greek patients with brucellosis: any role for clinical complications? European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, April 25-28, 2015.
38. G.V. Papatheodoridis, R. Idilman, G.N. Dalekos, M. Buti, H. Chi, F. van Bömmel, J.L. Calleja, V. Sypsa, I. Goulis, S. Manolakopoulos, F. Invernizzi, S.I. Siakavellas, O. Keskin, **N. Gatselis**, B.E. Hansen, M. Lehretz, J. de la Revilla, S. Savvidou, A. Kourikou, F. Facchetti, J. Vlachogiannakos, K. Galanis, C. Yurdaydin, T. Berg, M. Colombo, R. Esteban, H.L. Janssen, P. Lampertico. Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. The Liver Meeting 2015, American Association for the Study of Liver Diseases. San Francisco, CA, USA, November 13-17, 2015.
39. K. Azariadis, **N.K. Gatselis**, K. Zachou, V. Lygoura, P. Arvaniti, E.I. Rigopoulou, G. Papadamou, G.K. Koukoulis, G.N. Dalekos. Geoepidemiology of Primary Biliary Cirrhosis in Central Greece. 8th Larissa International Congress of Internal Medicine. Larissa, Greece, March 17-19, 2016.
40. V. Lygoura, **N.K. Gatselis**, K. Zachou, K. Azariadis, P. Arvaniti, G.K. Koukoulis, G.N. Dalekos. Hepatic steatosis and/or steatohepatitis in primary biliary cirrhosis: An innocent bystander or a guilty player? 8th Larissa International Congress of Internal Medicine. Larissa, Greece, March 17-19, 2016.
41. K. Azariadis, P. Arvaniti, K. Zachou, G.N. Dalekos, **N.K. Gatselis**. Autoimmune hepatitis: Impact of age at disease onset on disease severity, outcome and response to treatment. 8th Larissa International Congress of Internal Medicine. Larissa, Greece, March 17-19, 2016.
42. P. Arvaniti, K. Azariadi, **N. Gatselis**, G.N. Dalekos, K. Zachou. Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis and the need of liver transplantation. 8th Larissa International Congress of Internal Medicine. Larissa, Greece, March 17-19, 2016.
43. A. Stefanos, P. Lalou, M. Boulbou, S. Georgiadou, **N. Gatselis**, K. Makaritsis, G.N. Dalekos, E.I. Rigopoulou. Secondary haemophagocytic syndrome revisited: A 6-years real-life world study on presentation, aetiology and treatment. 8th Larissa International Congress of Internal Medicine. Larissa, Greece, March 17-19, 2016.
44. K. Azariadi, **N. Gatselis**, K. Zachou, E. Petinaki, G.N. Dalekos, S. Georgiadou. Autochthonous plasmodium vivax infection in Larissa: One of six cases in our country during 2015. 8th Larissa International Congress of Internal Medicine. Larissa, Greece, March 17-19, 2016.
45. M. Tsitsia, V. Syrmou, **N. Gatselis**, C. Rountas, G.K. Koukoulis, G.N. Dalekos, K. Zachou. Hepatocellular carcinoma occurring 24 years after treatment for Hodgkin's lymphoma. 8th Larissa International Congress of Internal Medicine. Larissa, Greece, March 17-19, 2016.
46. V. Ligoura, **N.K. Gatselis**, K. Zachou, K. Azariadi, P. Arvaniti, E.I. Rigopoulou, G.K. Koukoulis, G.N. Dalekos. Hepatic steatosis and/or steatohepatitis in primary

- biliary cholangitis (PBC): An innocent bystander or a guilty player? 15th European Congress of Internal Medicine – European Federation of Internal Medicine. Amsterdam, September 2-3, 2016.
47. K. Azariadi, **N.K. Gatselis**, K. Zachou, E. Perinaki, G.N. Dalekos, S. Georgiadou. Autochthonous plasmodium vivax infection in Larissa: one of six cases in our country during 2015. 15th European Congress of Internal Medicine – European Federation of Internal Medicine. Amsterdam, September 2-3, 2016.
 48. K. Azariadi, P. Arvaniti, K. Zachou, G.N. Dalekos, **N.K. Gatselis**. Autoimmune Hepatitis (AIH): Impact of age at disease onset on disease severity, outcome and response to treatment. 15th European Congress of Internal Medicine – European Federation of Internal Medicine. Amsterdam, September 2-3, 2016.
 49. K. Zachou, **N. Gatselis**, P. Arvaniti, K. Azariadi, V. Lygoura, E. Rigopoulou, G.N. Dalekos. Patients with hemoglobinopathies and chronic hepatitis C: Is it a difficult to treat population? 15th European Congress of Internal Medicine – European Federation of Internal Medicine. Amsterdam, September 2-3, 2016.
 50. P. Arvaniti, K. Azariadi, **N. Gatselis**, G.N. Dalekos, K. Zachou. Prompt initiation of intravenous corticosteroids prevents deterioration of acute/sever autoimmune hepatitis (AS-AIH) and the need of liver transplantation (LT). 15th European Congress of Internal Medicine – European Federation of Internal Medicine. Amsterdam, September 2-3, 2016.
 51. **N.K. Gatselis**, K.P. Makaritsis, P. Skendros, K. Ritis, G.N. Dalekos. Severe liver involvement in two patients with long-term history of fever: Remember Familial Mediterranean Fever. 15th European Congress of Internal Medicine – European Federation of Internal Medicine. Amsterdam, September 2-3, 2016.
 52. K. Azariadi, P. Arvaniti, K. Zachou, A. Saitis, G.N. Dalekos, **N. Gatselis**. Autoimmune hepatitis: Impact of age at disease onset on disease severity, outcome and response to treatment. The Liver Meeting 2016, American Association for the Study of Liver Diseases. Boston, MA, USA, November 11-15, 2016.
 53. G.V. Papatheodoridis, C. Yurdaydin, G.N. Dalekos, M. Buti, H. Chi, F. van Bömme, J.L. Calleja, V. Sypsa, I. Goulis, S. Manolakopoulos, A. Loglio, S.I. Siakavellas, O. Keskin, **N. Gatselis**, B.E. Hansen, M. Lehretz, J. de la Revilla, S. Savvidou, A. Kourikou, J. Vlachogiannakos, R. Idilman, K. Galanis, T. Berg, M. Colombo, R. Esteban, H.L. Janssen, P. Lampertico. The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. The Liver Meeting 2016, American Association for the Study of Liver Diseases. Boston, MA, USA, November 11-15, 2016.
 54. I.S. Elefsiniotis, G.N. Dalekos, J. Koskinas, P. Ioannidou, E. Cholongitas, S. Manolakopoulos, J. Goulis, J. Vlachogiannakos, M. Deutsch, C.K. Triantos, A. Kapatais, V.A. Sevastianos, M.J. Schina, S. Karatapanis, I. Ketikoglou, E.K. Manesis, M-V. Papageorgiou, E. Sinakos, **N.K. Gatselis**, D. Karagiannakis, A. Tasovasili, A. Koukoufiki, T.A. Voulgaris, C. Tsolias, E. Akriviadis, G.V. Papatheodoridis. Daclatasvir (DCV) plus Sofosbuvir (SOF) regimens in chronic Hepatitis C Virus (HCV) infected patients with advanced fibrosis or cirrhosis. The Liver Meeting 2016, American Association for the Study of Liver Diseases. Boston, MA, USA, November 11-15, 2016.

55. J. Vlachogiannakos, A. Kapatais, I.S. Elefsiniotis, J. Koskinas, M-V. Papageorgiou, S. Manolakopoulos, **N. Gatselis**, E. Cholongitas, M. Deutsch, S. Karatapanis, I. Ketikoglou, V.A. Sevastianos, J. Goulis, E.K. Manesis, D. Karagiannakis, T. Karaoulani, M. Tampaki, A. Tasovasili, P. Ioannidou, A. Kourikou, E. Sinakos, G. Ntetskas, T. Voulgaris, A. Koukoufiki, E. Akriviadis, G. N. Dalekos, G.V. Papatheodoridis. Efficacy and safety of ombitasvir (OBV) and ritonavir boosted paritaprevir (PRV/r) with or without dasabuvir (DSV) regimens in genotype 1 or 4 HCV infected patients. A Greek multicenter real-life cohort study. The Liver Meeting 2016, American Association for the Study of Liver Diseases. Boston, MA, USA, November 11-15, 2016.
56. D.N. Samonakis, **N. Gatselis**, D. Sifaki-Pistola, A-L. Bellou, M. Mela, E. Thalassinou, K. Zachou, E. Digenakis, E.A. Kouroumalis, G.N. Dalekos, T.G. Vasileiadis. Spontaneous Bacterial Peritonitis in cirrhosis: a Prospective Multicenter Study of Clinical, Microbiological characteristics and Predictors of 6 months Survival. The Liver Meeting 2016, American Association for the Study of Liver Diseases. Boston, MA, USA, November 11-15, 2016.
57. G.V. Papatheodoridis, G.N. Dalekos, C. Yurdaydin, F. van Bömmel, M. Buti, V. Sypsa, J. Goulis, J.L. Calleja, H. Chi, S. Manolakopoulos, A. Loglio, **N. Gatselis**, O. Keskin, M. Lehretz, S. Savvidou, J. de la Revilla, B.E. Hansen, J. Vlachogiannakos, K. Galanis, R. Idilman, M. Colombo, R. Esteban, H.L. Janssen, T. Berg, P. Lampertico. Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy. The Liver Meeting 2016, American Association for the Study of Liver Diseases. Boston, MA, USA, November 11-15, 2016.
58. **N. Gatselis**, V. Ligoura, K Zachou, K. Azariadi, P. Arvaniti, E.I. Rigopoulou, G.K. Koukoulis, G.N. Dalekos. Hepatic steatosis and/or steatohepatitis in primary biliary cholangitis: An innocent bystander or a guilty player? The Liver Meeting 2016, American Association for the Study of Liver Diseases. Boston, MA, USA, November 11-15, 2016.
59. M. Papatheodoridi, E. Hadziyannis, E. Rigopoulou, K. Zachou, V. Xourafas, A. Lyberopoulou, **N.K. Gatselis**, S. Manolakopoulos, G.N. Dalekos, G. Papatheodoridis. Interferon-induced protein-10 (IP10) at entecavir (ETV) or tenofovir (TDF) discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) cannot predict subsequent relapses. DARING-B: Prospective Greek study. 9th International Congress of Internal Medicine. Athens, March 9-11, 2017.
60. K. Azariadi, V. Ligoyra, K. Zachou, P. Arvaniti, A. Saitis, **N.K. Gatselis**, G.K. Koukoulis, G.N. Dalekos. Characteristics of Greek male patients with primary biliary cholangitis (PBC). 9th International Congress of Internal Medicine. Athens, March 9-11, 2017.
61. K. Azariadi, P. Arvaniti, **N.K. Gatselis**, G.K. Koukoulis, G.N. Dalekos, K. Zachou. Severe acute non-A, non-B, non-C hepatitis with autoimmune features: Consider acute hepatitis E virus (HEV) infection not just autoimmune hepatitis (AIH). 9th International Congress of Internal Medicine. Athens, March 9-11, 2017.
62. K. Zachou, P. Arvaniti, **N.K. Gatselis**, K. Azariadi, G. Papadamou, E. Rigopoulou, G.N. Dalekos. Patients with haemoglobinopathies and chronic

hepatitis C: Really difficult to treat population in 2016? 9th International Congress of Internal Medicine. Athens, March 9-11, 2017.

63. P. Arvaniti, K. Azariadi, V. Lygoura, **N. Gatselis**, G.K. Koukoulis, G.N. Dalekos, K. Zachou. Postinfantile giant cell hepatitis (PIGCH): A rare histological presentation of autoimmune hepatitis leading to fulminant liver failure. 9th International Congress of Internal Medicine. Athens, March 9-11, 2017.
64. K. Azariadi, P. Arvaniti, M. Tsitsia, K. Zachou, G. Papadamou, A. Loukopoulos, **N.K. Gatselis**, K.P. Makaritsis, G.K. Koukoulis, G.N. Dalekos. Glycogenic hepatopathy: An unusual hepatic complication of diabetes mellitus. 9th International Congress of Internal Medicine. Athens, March 9-11, 2017.
65. E. Polychronopoulou, P. Arvaniti, D. Sagris, A. Loukopoulos, G. Papadamou, **N.K. Gatselis**, K.P. Makaritsis, G.K. Koukoulis, G.N. Dalekos. A patient with unusual presentation of visceral leishmaniasis: Thinking outside the box. 9th International Congress of Internal Medicine. Athens, March 9-11, 2017.
66. G. Papatheodoridis, E. Rigopoulou, M. Papatheodoridi, K. Zachou, V. Xourafas, **N. Gatselis**, J. Vlachogiannakos, G. Dalekos. DARING-B: discontinuation of effective entecavir or tenofovir therapy in non-cirrhotic HBeAg-negative chronic hepatitis B patients: a prospective Greek study. The International Liver Congress 2017. European Association for the Study of the Liver. Amsterdam, The Netherlands, April 19-23, 2017. [oral presentation]
67. A. Wranke, S. Hardtke, L.M.P. Borzacov, R. Parana, C. Lobato, S. Hamid, E. Ceausu, G.N. Dalekos, M. Rizzetto, A. Turcanu, G. Niro, T. Hayden, M. Abbas, P. Ingiliz, M. Buti, P. Ferenci, T. Vanwolleghem, A. Motoc, Z. Abbas, C. Yurdaydin, M.P. Manns, H. Wedemeyer, B.C. Serrano, M. Wöbse, B. Heidrich, M. Mucic, **N.K. Gatselis**, K. Zachou, A. Smedile, R. Gish, D. Obretin, R. Stern, E. Ho, P. Michielsen, O.D. Valentina, F. Lubna, R. Fontana. Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network. The International Liver Congress 2017. European Association for the Study of the Liver. Amsterdam, The Netherlands, April 19-23, 2017.
68. K. Zachou, P. Arvaniti, **N.K. Gatselis**, K. Azariadi, G.K. Koukoulis, G.N. Dalekos. Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis (AS-AIH) and the need for liver transplantation (LT). The International Liver Congress 2017. European Association for the Study of the Liver. Amsterdam, The Netherlands, April 19-23, 2017. **Η ανωτέρω εργασία επιλέχθηκε για προφορική παρουσίαση κατά τη διάρκεια του συνεδρίου (poster tour).**
69. G. Papatheodoridis, A. Kapatais, E. Sinakos, I. Elefsiniotis, J. Goulis, M. Deutsch, J. Vlachogiannakos, G. Dalekos, J. Koskinas, S. Karatapanis, M. Schina, E. Manesis, I. Ketikoglou, V. Sevastianos, C. Triantos, E. Cholongitas, M.-V. Papageorgiou, A. Kourikou, T. Karaoulani, E. Evangelidou, A. Koukoufiki, D. Karagiannakis, **N. Gatselis**, M. Tampaki, G. Ntetskas, C. Tsolias, T. Voulgaris, P. Ioannidou, E. Akriviadis, S. Manolakopoulos. Platelets represent an independent predictor of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral(s) (DAA). HERACLIS: Hellenic multicenter real-life cohort study. The

International Liver Congress 2017. European Association for the Study of the Liver. Amsterdam, The Netherlands, April 19-23, 2017.

70. J.C. Goet, W.J. Lammers, A. Floreani, A. Pares, H.L.A. Janssen, G.M. Hirschfield, H.R. Van Buuren, C. Corpechot, P. Invernizzi, K.D. Lindor, M.J. Mayo, P.M. Battezzati, F. Nevens, A.L. Mason, K.V. Kowdley, C.Y. Ponsioen, T. Bruns, G.N. Dalekos, D. Thorburn, X. Verhelst, **N.K. Gatselis**, P.J. Trivedi, R. Poupon, B.E. Hansen and The Global PBC Study Group. The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time. The International Liver Congress 2017. European Association for the Study of the Liver. Amsterdam, The Netherlands, April 19-23, 2017. **Η ανωτέρω εργασία επιλέχθηκε για προφορική παρουσίαση κατά τη διάρκεια του συνεδρίου (poster tour).**
71. **N.K. Gatselis**, K. Zachou, V. Lygoura, K. Azariadis, P. Arvaniti, E. Spyroul, G. Papadamou, G.K. Koukoulis, G.N. Dalekos, E.I. Rigopoulou. Geoepidemiology, clinical manifestations and outcome of a large cohort of primary biliary cholangitis patients in Greece. The International Liver Congress 2017. European Association for the Study of the Liver. Amsterdam, The Netherlands, April 19-23, 2017.
72. K. Azariadis, V. Lygoura, K. Zachou, P. Arvaniti, A. Saitis, **N.K. Gatselis**, G.N. Dalekos. Characteristics of Greek male patients with primary biliary cholangitis. The International Liver Congress 2017. European Association for the Study of the Liver. Amsterdam, The Netherlands, April 19-23, 2017.
73. A.I. Saitis, **N.K. Gatselis**, K. Azariadis, K. Zachou, G. Papadamou, E. Rigopoulou, G.K. Koukoulis, G.N. Dalekos. Wilson's disease: A single Greek center experience. 16th European Congress of Internal Medicine – European Federation of Internal Medicine. Milan, Italy, August 31 - September 2, 2017.
74. **N.K. Gatselis**, P. Skendros, A.I. Saitis, K. Ritis, G.N. Dalekos. Familial Mediterranean Fever (FMF): A single center experience. 16th European Congress of Internal Medicine – European Federation of Internal Medicine. Milan, Italy, August 31 - September 2, 2017.
75. V. Lygoura, P. Arvaniti, K. Azariadi, **N.K. Gatselis**, G.K. Koukoulis, G.N. Dalekos, K. Zachou. Diagnostic accuracy of transient elastography for liver fibrosis evaluation in patients with autoimmune hepatitis: Preliminary results. 16th European Congress of Internal Medicine – European Federation of Internal Medicine. Milan, Italy, August 31 - September 2, 2017.
76. **N.K. Gatselis**, J.C. Goet, K. Zachou, W.J. Lammers, H.L.A. Janssen, G. Hirschfield, C. Corpechot, K.D. Lindor, P. Invernizzi, M.J. Mayo, P.M. Battezzati, A. Floreani, A. Pares, V. Lygoura, F. Nevens, A.L. Mason, K.V. Kowdley, C.Y. Ponsioen, T. Bruns, D. Thorburn, X. Verhelst, M.H. Harms, H.R. van Buuren, B.E. Hansen, G.N. Dalekos - on behalf of the Global PBC Study Group. Moving from early to moderate or advanced biochemical disease stage during follow-up is associated with an increasing risk of clinical events in primary biliary cholangitis patients. The Liver Meeting 2017, American Association for the Study of Liver Diseases. Washington, DC, USA, October 20-24, 2017.
77. G.V. Papatheodoridis. E.I. Rigopoulou, M. Papatheodoridi, K. Zachou, V. Xourafas, **N.K. Gatselis**, J. Vlachogiannakos, S. Manolakopoulos, G. Dalekos.

DARING-B. Discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) patients: final results of a prospective Greek study. The Liver Meeting 2017, American Association for the Study of Liver Diseases. Washington, DC, USA, October 20-24, 2017.

78. G.V. Papatheodoridis, J. Koskinas, I. Goulis, E. Sinakos, G. Dalekos, A. Kapatais, M. Oikonomopoulou, J. Vlachogiannakos, I.S. Elefsiniotis, M. Deutsch, T.G. Vasileiadis, D.N. Samonakis, I. Ketikoglou, S. Karatapanis, E.K. Manesis, K. Mimidis, A. Alexopoulou, M.J Schina, C.K. Triantos, V.A. Sevastianos, N. Papadopoulos, P. Ioannidou, A. Kourikou, I. Petalidis, A. Koukoufiki, **N.K. Gatselis**, T. Karaoulani, D. Karagiannakis, E. Evangelidou, A-L. Bellou, M. Koulentaki, G. Ntetskas, T. Mylopoulou, C. Tsolias, D.V. Lymperopoulos, M.V. Papageorgiou, H. Kranidioti, E. Koulias, E. Orfanoudaki, T. Voulgaris, E. Cholongitas, E. Akriadiadis, S. Manolakopoulos. Changes in the use of direct acting antiviral(s) (DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. HERACLIS: a Hellenic multicenter real-life cohort clinical study. The Liver Meeting 2017, American Association for the Study of Liver Diseases. Washington, DC, USA, October 20-24, 2017.
79. 162. G. Dalekos, J. Vlachogiannakos, E.K. Manesis, J. Goulis, K. Mimidis, M. Oikonomopoulou, P. Ioannidou, A. Kourikou, **N.K. Gatselis**, M.-V. Papageorgiou, D. Karagiannakis, A. Koukoufiki, E. Evangelidou, T. Mylopoulou, H. Kranidioti, T. Voulgaris, S. Manolakopoulos, I.S. Elefsiniotis, G.V. Papatheodoridis. Regression of liver stiffness following therapy with direct acting antiviral(s) in chronic hepatitis C patients. Results from HERACLIS: a Hellenic multicenter real-life cohort clinical study. The Liver Meeting 2017, American Association for the Study of Liver Diseases. Washington, DC, USA, October 20-24, 2017.
80. M. Bakarozi, K. Galanis, S. Gabeta, K. Zachou, **N.K. Gatselis**, G.N. Dalekos, E.I. Rigopoulou. Assessment of health related quality of life in Greek patients with primary biliary cholangitis using the PBC-40 questionnaire. 10th International Congress of Internal Medicine. Athens, March 22-24, 2017. [oral presentation]
81. **N.K. Gatselis**, J.C. Goet, K. Zachou, W.J. Lammers, H.L.A. Janssen, G. Hirschfield, C. Corpechot, K.D. Lindor, P. Invernizzi, M.J. Mayo, P.M. Battezzati, A. Floreani, A. Pares, V. Lygoura, F. Nevens, A.L. Mason, K.V. Kowdley, C.Y. Ponsioen, T. Bruns, D. Thorburn, X. Verhelst, M.H. Harms, H.R. van Buuren, B.E. Hansen, G.N. Dalekos. Moving from early to moderate or advanced biochemical disease stage during follow-up is associated with an increasing risk of clinical events in primary biliary cholangitis patients. 10th International Congress of Internal Medicine. Athens, March 22-24, 2017. [oral presentation]
82. A. Saitis, **N.K. Gatselis**, K. Azariadi, K. Zachou, G.K. Koukoulis, G.N. Dalekos. Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus infection. 10th International Congress of Internal Medicine. Athens, March 22-24, 2017. [oral presentation]
83. D. Sagris, A. Saitis, **N.K. Gatselis**, P. Skendros, E.I. Rigopoulou, K.P. Makaritsis, K. Zachou, K. Ritis, G.N. Dalekos. Familial Mediterranean Fever: A

single Greek center experience. 10th International Congress of Internal Medicine. Athens, March 22-24, 2017. [oral presentation]

84. M. Papatheodoridis, E. Rigopoulou, E. Hadziyannis, Z. Kalliopi, V. Xourafas, A. Lyberopoulou, **N. Gatselis**, I. Vlachogiannakos, S. Manolakopoulos, G. Dalekos, G. Papatheodoridis. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non- cirrhotic HBeAg-negative chronic hepatitis B patients: Results from the DARING-B prospective Greek study. The International Liver Congress 2018. European Association for the Study of the Liver. Paris, France, April 11-15, 2018. [oral presentation].
85. A. Samakidou, A. Stefos, S. Georgiadou, **N. Gatselis**, K. Zachou, V. Kontogeorgakos, E. Petinaki, G. Dalekos. Multifocal pyomyositis, septic arthritis, osteomyelitis, empyema and bacteremia due to CA-MRSA in a male adult with hemophilia, treated with combination of daptomycin and vancomycin. 18th European Congress of Internal Medicine, European Federation of Internal Medicine, Wiesbaden, Germany, August 30 - September 1, 2018. [poster presentation].
86. G.V. Papatheodoridis, G.N. Dalekos, C. Yurdaydin, V. Sypsa, F. Van Bommel, M. Buti, J.L. Calleja, H. Chi, I. Goulis, S. Manolakopoulos, A. Loglio, S. Siakavellas, **N.K. Gatselis**, O. Keskin, R. Veelken, M. Lopez-Gomez, B.E. Hansen, S. Savvidou, A. Kourikou, I. Vlachogiannakos, K. Galanis, R. Idilman, R. Esteban, H.L.A. Janssen, T. Berg, P. Lampertico. Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Causasian chronic hepatitis B (CHB) patients of the PAGE-B cohort. The Liver Meeting 2018, American Association for the Study of Liver Diseases. San Francisco, DC, USA, November 09-13, 2018. [poster presentation]
87. C.F. Murillo Perez, A. Gulamhusein, C. Corpechot, A. van der Meer, H.R. van Buure, P. Invernizzi, P. Trivedi, F. Nevens, M.J. Mayo, P.M. Battezzati, W.J. Lammers, A. Floreani, A. Pares, M. Carbone, K.V. Kowdley, T. Bruns, J.C. Goet, C.Y. Ponsioen, G.N. Dalekos, D. Thorburn, A. Mason, N.F. LaRusso, **N.K. Gatselis**, R. Poupon, X. Verhelst, K.D. Lindor, H.L.A. Janssen, G. Hirschfield, B.E. Hansen. Alkaline phosphatase normalization is associated with as decreased risk for liver transplantation and death in patients with primary biliary cholangitis. The Liver Meeting 2018, American Association for the Study of Liver Diseases. San Francisco, DC, USA, November 09-13, 2018. [poster presentation]
88. M. Papatheodoridi, E. Hadziyannis, F. Berby, E. Rigopoulou, K. Zachou, B. Testoni, A. Lyberopoulou, **N.K. Gatselis**, I. Vlachogiannakos, S. Manolakopoulos, G.N. Dalekos, F. Zoulim, G.V. Papatheodoridis. Predictability of serum HBcrAg, HBsAg and interferon inducible protein 10 (IP10) levels in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue entecavir (ETV) or Tenofovir (TDF) therapy: Results from the prospective DARING-B study. The Liver Meeting 2018, American Association for the Study of Liver Diseases. San Francisco, DC, USA, November 09-13, 2018. [poster presentation]
89. C.F. Murillo Perez, A. Gulamhusein, M. Carbone, P. Trivedi, A. van der Meer, C. Corpechot, P.-M. Battezzati, W. Lammers, A. Floreani, A. Pares, F. Nevens, M. Mayo, K. Kowdley, C. Ponsioen, G. Dalekos, D. Thorburn, A. Mason, **N.**

- Gatselis**, X. Verhelst, T. Bruns, H. Janssen, K. Lindor, O. Chazouilleres, P. Invernizzi, B. Hansen, G. Hirschfield. Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test. Canadian Liver Meeting. Montreal, Canada, May 24-26, 2019. [poster presentation]
90. J. Goet, M. Harms, A. Floreani, T. Bruns, F. Prechter, H. Janssen, G. Dalekos, V. Xavier, C. Corpechot, P. Invernizzi, M.J. Mayo, P.M. Battezzati, F. Nevens, A.L. Mason, K.V. Kowdley, C. Ponsioen, D. Thorburn, A. Reig, K.D. Lindor, W.J. Lammers, **N. Gatselis**, G. Hirschfield, B. Hansen, A. van der Meer, A. Parés, H. Van Buuren. Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis. The International Liver Congress 2019. European Association for the Study of the Liver. Vienna, Austria, April 10-14, 2019. [poster presentation]
91. K. Zachou, K. Azariadi, E. Lytvyak, **N. Gatselis**, A. Takahashi, M. Robles, R. Andrade, C. Schramm, A.W. Lohse, A. Tanaka, A.J. Montano-Loza, G.N. Dalekos. Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander? The International Liver Congress 2019. European Association for the Study of the Liver. Vienna, Austria, April 10-14, 2019. [poster presentation]
92. C.F. Murillo Perez, A. Gulamhusein, M. Carbone, P. Trivedi, A. Van der Meer, C. Corpechot, P.M. Battezzati, W.J. Lammers, A. Floreani, A. Parés, H. Nan Buuren, F. Nevens, M.J. Mayo, K.V. Kowdley, C. Ponsioen, G. Dalekos, D. Thorburn, A.L. Mason, **N. Gatselis**, V. Xavier, T. Bruns, H.J. Janssen, K.D. Lindor, O. Chazouillères, P. Invernizzi, B. Hansen, G. Hirschfield. Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test. The International Liver Congress 2019. European Association for the Study of the Liver. Vienna, Austria, April 10-14, 2019. [poster presentation]
93. G. Papatheodoridis, G. Dalekos, C. Yurdaydin, V. Sypsa, F. van Bömmel, M. Buti, J.L. Calleja Panero, H. Chi, I. Goulis, S. Manolakopoulos, A. Loglio, T. Voulgaris, **N. Gatselis**, O. Keskin, R. Veelken, M. López-Gómez, B. Hansen, S. Savvidou, A. Kourikou, I. Vlachogiannakos, K. Galanis, R. Idilman, R. Esteban, H. Janseen, T. Berg, P. Lampertico. Prediction of elastographic reversion or cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in Caucasian chronic hepatitis B patients. The International Liver Congress 2019. European Association for the Study of the Liver. Vienna, Austria, April 10-14, 2019. [poster presentation]
94. E. Giannitsioti, A. Pefanis, G. Adamis, N. Alexiou, A. Andrianaki, M. Argyriou, A. Vrettou, P. Gargalianos-Kakolyris, **N. Gatselis**, S. Georgiadou, C. Gogos, G. Daikos, G. Dalekos, K. Evdoridis, I. Karaiskos, E. Kostis, Kofteridis, A. Lekkou, C. Loupa, P. Lourida, E. Maltezos, A. Masgala, P. Nikou, P. Panagopoulos, A. Rigopoulos, V. Sachpekidis, V.N. Sipsas, D. Sinapidis, S. Sympardi, C. Tryfonopoulos, T. Tsaganos, H. Giamarellou, on behalf of the Hellenic Society of Chemotherapy. Early surgery for infective endocarditis: Results for a multi-centre nationwide epidemiological study. 15th International Society of Cardiovascular Infectious Diseases Symposium. [poster presentation]
95. D. Sagris, **N.K. Gatselis**, P. Skendros, A. Stefos, A. Saitis, E.I. Rigopoulou, K.P. Makaritsis, K. Zachou, K. Ritis, G.N. Dalekos. The diverse face of Familial

Mediterranean Fever (FMF) in Greece: The importance of R202Q mutation of Mediterranean Fever (MEFV) gene. 18th European Congress of Internal Medicine. Lisbon, Portugal, 29-31 August, 2019. [oral presentation] **This study was awarded as the best research study of the congress (1st award).**

96. V. Lygoura, **N.K. Gatselis**, K. Galanis, G. Giannoulis, S. Gabeta, K. Zachou, E.I. Rigopoulou, G.N. Dalekos. The changing epidemiology of hepatitis B in Greece. 18th European Congress of Internal Medicine. Lisbon, Portugal, 29-31 August, 2019. [oral e-poster presentation]
97. K. Zachou, K. Azariadis, E. Lytvyak, **N.K. Gatselis**, A. Takahashi, M. Robles, R.J. Andrade, C. Schramm, A.W. Lohse, A. Tanaka, E. Rigopoulou, A.J. Montano-Loza, G.N. Dalekos on behalf of the IAIHG. Non-alcoholic fatty liver disease in autoimmune hepatitis: Important player or innocent bystander? An international multicenter study of the IAIHG. 18th European Congress of Internal Medicine. Lisbon, Portugal, 29-31 August, 2019. [oral e-poster presentation]
98. K. Azariadis, **N.K. Gatselis**, P. Arvaniti, V. Lygoura, S. Gampeta, K. Zachou, G.N. Dalekos. Autoimmune hepatitis (AIH): The impact of ageing on severity, treatment response and outcome of autoimmune hepatitis. 18th European Congress of Internal Medicine. Lisbon, Portugal, 29-31 August, 2019. [oral e-poster presentation]

(*98 additional oral presentation / posters in Greek congresses)

• DOCTORAL THESIS

“Non-organ specific autoantibodies and autoantibodies correlated with autoimmune liver diseases in patients with chronic hepatitis C under treatment with interferon- α with or without ribavirin”, Larissa, 2006.

Parts of my Doctoral Thesis have been published as full papers in *World Journal of Gastroenterology and Alimentary Pharmacology and Therapeutics* (see International Publications No: 3 and 12).

• PAPERS IN INTERNATIONAL MEDICAL JOURNAL

1. G.N. Dalekos, K. Zachou, Ch. Liaskos, **N. Gatselis**. Autoantibodies and defined target-autoantigens in autoimmune hepatitis: An overview. *Eur J Intern Med* 13: 293-303, 2002. [IF: 2.591]
2. K. Zachou, Ch. Liaskos, D.K. Christodoulou, M. Kardasi, G. Papadamou, **N. Gatselis**, S.P. Georgiadou, E.V. Tsianos, G.N. Dalekos. Anti-cardiolipin antibodies (anti-CL) in patients with chronic viral hepatitis are independent of beta2-glycoprotein I (b2GPI) co-factor of features of antiphospholipid syndrome. *Eur J Clin Invest* 33: 161-168, 2003. [IF: 2.687]
3. **N.K. Gatselis**, S.P. Georgiadou, N. Tassopoulos, K. Zachou, Ch. Liaskos. A. Hatzakis, G.N. Dalekos. Impact of parietal cell autoantibodies and non-organ-

specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study. *World J Gastroenterol* 11: 482-487, 2005. [IF: 2.787]

4. C. Liaskos, E. Rigopoulou, K. Zachou, S. Georgiadou, **N. Gatselis**, R. Papamichali, G.N. Dalekos. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. *J Autoimmun* 24: 251-260, 2005. [IF: 7.760]
5. E.K. Zervou, **N.K. Gatselis**, E. Xanthi, K. Ziciadis, S.P. Georgiadou, G.N. Dalekos. Intrafamilial spread of hepatitis B virus infection in Greece. *Eur J Gastroenterol Hepatol* 17: 911-915, 2005. [IF: 2.093]
6. E.K. Zervou, S.P. Georgiadou, G.K. Liapi, F. Karabini, V. Giogiakas, K. Zisiadis, **N.K. Gatselis**, I. Goudevenos, G.N. Dalekos. Markers of hepatitis viruses and human T-lymphotropic virus type I/II in patients who have undergone open-heart surgery: Evidence of increased risk for exposure to HBV and HEV. *Eur J Intern Med* 16:424-428, 2005. [IF: 2.591]
7. **N. Gatselis**, E. Mali, G. Papadamou, E. Petinaki, G.N. Dalekos. Direct detection of *Cardiobacterium hominis* by broad-range bacterial polymerase chain reaction in serum from a patient with infective endocarditis. *J Clin Microbiol* 44:669-672, 2006. [IF: 3.631]
8. N. Tzovaras, A. Stefos, S.P. Georgiadou, **N. Gatselis**, G. Papadamou, E. Rigopoulou, M. Ioannou, I. Skoularigis, N. Dalekos. Reversion of severe hepatopulmonary syndrome in a non-cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: A case report and review of the literature. *World J Gastroenterol* 14: 336-339, 2006. [IF: 2.787]
9. K. Zachou, C. Liaskos, E. Rigopoulou, S. Gabeta, P. Papamichalis, **N. Gatselis**, S. Georgiadou, G.N. Dalekos. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. *Clin Immunol* 119: 203-212, 2006. [IF: 4.034]
10. T.A. Zografos, E.I. Rigopoulou, C. Liaskos, E. Togousidis, K. Zachou, **N. Gatselis**, A. Germenis, G.N. Dalekos. Alterations of leptin during IFN- α therapy in patients with chronic viral hepatitis. *J Hepatol* 44: 848-855, 2006. [IF: 10.590]
11. N. Stefanou, M. Satra, V. Papanikolaou, F. Kalala, **N. Gatselis**, A. Germenis, G.N. Dalekos, A. Tsezou. Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. *Exp Biol Med (Maywood)* 231:1653-1663, 2006. [IF: 2.542]
12. **N.K. Gatselis**, S.P. Georgiadou, G.K. Koukoulis, N. Tassopoulos, K. Zachou, C. Liaskos, A. Hatzakis, G.N. Dalekos. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. *Aliment Pharmacol Ther* 24:1563-1573, 2006. [IF: 6.320]
13. E. Tsironi, **N. Gatselis**, M.G. Kotoula, D.Z. Chatzoulis, G.N. Dalekos. Unexplained choroidal embolization: remember the antiphospholipid syndrome. *Lancet* 368:1936, 2007. [IF: 44.002]
14. M. Satra, **N. Gatselis**, D. Iliopoulos, D. Zacharoulis, G.N. Dalekos, A. Tsezou. Real-time quantification of human telomerase reverse transcriptase mRNA in

- liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. *J Viral Hepat* 14:41-47; 2007. [IF: 4.179]
15. **N.K. Gatselis**, E. Rigopoulou, A. Stefos, M. Kardasi, G.N. Dalekos. Risk factors associated with HCV infection in semi-rural areas of central Greece. *Eur J Intern Med* 18:48-55, 2007. [IF: 2.591]
 16. **N.K. Gatselis**, A. Stefos, C. Gioti, E.I. Rigopoulou, G.N. Dalekos. Primary biliary cirrhosis and Henoch-Schonlein purpura: report of two cases and review of the literature. *Liver Int* 27:280-283, 2007. [IF: 4.470]
 17. **N.K. Gatselis**, K. Tepetes, A. Loukopoulos, K. Vasiou, A. Zafiriou, C. Gioti, G.N. Dalekos. Hepatitis B virus and intrahepatic cholangiocarcinoma. *Cancer Invest* 25: 55-58, 2007. [IF: 2.231]
 18. **N.K. Gatselis**, S. Barbanis, F. Karasavidou, G.N. Dalekos. Could the 90s be a second childhood period? The case of Henoch-Schonlein purpura. *Age Ageing* 37: 483, 2008. [IF: 4.201]
 19. S. Gabeta, G.L. Norman, **N. Gatselis**, C Liaskos, P.A. Papamichalis, A. Garagounis, K. Zachou, E.I. Rigopoulou, G.N. Dalekos. IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases. *J Clin Immunol* 28(: 501-511, 2008. [IF: 3.094]
 20. K.P. Makaritsis, **N.K. Gatselis**, M. Ioannou, E. Petinaki, G.N. Dalekos. Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. *Int J Infect Dis* 13: e157-60, 2009. [IF: 2.229]
 21. E. Kapsalaki, **N. Gatselis**, A. Stefos, K. Makaritsis, A. Vassiou, I. Fezoulidis, G.N. Dalekos. Spontaneous spondylodiscitis: presentation, risk factors, diagnosis, management, and outcome. *Int J Infect Dis* 13: 564-9, 2009. [IF: 2.229]
 22. Stefos, **N. Gatselis**, K. Zachou, E. Rigopoulou, C. Hadjichristodoulou, G.N. Dalekos. Descriptive epidemiology of chronic hepatitis B by data from a hepatitis registry in central Greece. *Eur J Intern Med* 20: 35-43, 2009. [IF: 2.591]
 23. K.P. Makaritsis, C. Neocleous, **N. Gatselis**, E. Petinaki, G.N. Dalekos. An immunocompetent patient presenting with severe septic arthritis due to *Ralstonia pickettii* identified by molecular-based assays: a case report. *Cases J* 2: 8125, 2009. [IF: -]
 24. E. Tsironi, **N. Gatselis**, M.G. Kotoula, K. Zachou, M. Pefkianaki, D.Z. Chatzoulis, G.N. Dalekos. Ocular disorders as the prevailing manifestations of the antiphospholipid syndrome: A prospective study. *Cases J* 2: 159, 2009. [IF:]
 25. **N. Gatselis**, K. Zachou, P. Papamichalis, G.K. Koukoulis, S. Gabeta, G.N. Dalekos, E.I. Rigopoulou. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score? *Dig Liver Dis* 42: 807-812, 2010. [IF: 2.719]
 26. **N.K. Gatselis**, G.N. Dalekos. Hepatobiliary and Pancreatic: Primary Hepatic Lymphoma. *J Gastroenterol Hepatol* 26: 210, 2011. [IF: 3.322]
 27. **N.K. Gatselis**, K. Zachou, G.N. Dalekos. Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. *Gastroenterol Res Pract* 2010. pii: 121620. [IF: 1.742]

28. K. Zachou*, **N.K. Gatselis***, G.K. Koukoulis, E.I. Rigopoulou, G.N. Dalekos. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of patients. *J Hepatol* 55: 636-646, 2011 (*equally attributed). [IF: 10.590]
29. **N.K. Gatselis**, K.P. Makaritsis, I. Gabranis, K. Karanikas, G.N. Dalekos. Unusual cardiovascular complications of brucellosis: a case series. *J Med Case Reports* 5: 22, 2011.1 [IF: -]
30. K. Zachou K, K. Oikonomou K, Y. Renaudineau, A. Chauveau, **N. Gatselis**, P. Youinou, G.N. Dalekos. Anti- α -actin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. *Aliment Pharmacol Ther* 35:116-125, 2012. [IF: 6.320]
31. **N.K. Gatselis**, G. Liamis, K.P. Makaritsis, G.N. Dalekos. Metabolic acidosis during treatment of mushroom poisoning: A diagnostic pitfall. *Intern Med* 51:1077-1080, 2012. [IF: 0.832]
32. **N.K. Gatselis**, K. Zachou, G.L. Norman, G. Tzelas, M. Speletas, A. Germenis, G.K. Koukoulis, G.N. Dalekos. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. *Clin Chim Acta* 413: 1683-1688, 2012. [IF: 2.799]
33. T.A. Zografos, **N. Gatselis**, C. Liaskos, S. Gabeta, G.K. Koukoulis, G.N. Dalekos. Primary biliary cirrhosis-specific autoantibodies in first-degree relatives of Greek primary biliary cirrhosis patients. *World J Gastroenterol* 18: 4721-4728, 2012 [IF: 2.787]
34. Saitis, **N.K. Gatselis**, G.N. Dalekos. Leishmaniasis-associated haemophagocytic syndrome revisited: not an uncommon clinical presentation of leishmaniasis. *J Med Cases* 3:315-318, 2012. [IF: -]
35. Stefos, **N.K. Gatselis**, A. Goudelas, M. Mpakarozi, J. Papaparaskevas, G.N. Dalekos, E. Petinaki. Cutaneous infection caused by Bacillus Anthracis in Larissa, Thessaly, Central Greece, July 2012. *Eurosurveil* 17:pii=20245. [IF: 5.983]
36. **N.K. Gatselis**, G. Ntaios, K.P. Makaritsis, G.N. Dalekos. Adiponectin: a key playmaker in non-alcoholic fatty liver disease. *Clin Exp Med* 14: 212-31, 2013. [IF: 2.854]
37. G. Ntaios, **N.K. Gatselis**, K.P. Makaritsis, G.N. Dalekos. Adipokines as mediators of endothelial function and atherosclerosis. *Atherosclerosis* 227:216-221; 2013. [IF: 3.942]
38. Saitis, **N. Gatselis**, K. Zachou, G.N. Dalekos. Use of TNF α antagonists in refractory AIH: Revealing the unforeseen. *J Hepatol* 59: 197-198, 2013. [IF: 10.590]
39. Mazioti, **N. Gatselis**, C. Rountas, K. Zachou, D.K. Filippiadis, K. Tepetes, G.K. Koukoulis, I. Fezoulidis, G.N. Dalekos. Safety and efficacy of transcatheter chemoembolization in the real-life management of unresectable hepatocellular carcinoma. *Hepat Mon* 13:e7070, 2013. [IF: 1.932]
40. **N.K. Gatselis**, K. Zachou, G.L. Nornan, S. Gabeta, P. Papamichalis, G.K. Koukoulis, G.N. Dalekos. Clinical significance of the fluctuation of primary

biliary cirrhosis-related during the course of the disease. *Autoimmunity* 46:471-479, 2013. [IF: 2.917]

41. K. Zachou, A. Sarantopoulos, N.K. Gatselis, T. Vassiliadis, S. Gabeta, A. Stefos, A. Saitis, P. Boura, G.N. Dalekos. Hepatitis B reactivation in hepatitis B surface antigen negative receiving immunosuppression: A hidden threat. *World J Hepatol* 5: 387-392; 2013. [IF: -]
42. M. Pavlaki, G. Poulakou, P. Drimousis, G. Adamis, E. Apostolidou, N.K. Gatselis, I. Kritselis, A. Mega, V. Mylona, A. Papatsoris, A. Pappas, A. Prekates, M. Raftogiannis, K. Rigaki, K. Sereti, D. Sinapidis, I. Tsangaris, V. Tzanetakou, D. Veldekis, K. Mandragos, H. Giamarellou, G. Dimopoulos; on behalf of the Hellenic Sepsis Study Group. Polymicrobial sepsis: Epidemiology and impact of mortality. Polymicrobial bloodstream infections: Epidemiology and impact on mortality. *Journal of Global Antimicrobial Resistance* 1:207-212, 2013. [IF: 1.087]
43. K. Zachou, P. Muratori, G.K. Koukoulis, A. Granito, N. Gatselis, A. Fabbri, G.N. Dalekos, L. Muratori. Autoimmune hepatitis - current management and challenges. *Aliment Pharmacol Ther* 38:887-913, 2013. [IF: 6.320]
44. E.J. Giamarellos-Bourboulis, E. Apostolidou, M. Lada, I. Perdios, N.K. Gatselis, I. Tsangaris, M. Georgitsi, M. Bristianou, T. Kanni, K. Sereti, A. Kotanidou, A. Armaganidis; on behalf of the Hellenic Sepsis Study Group. Modulation of the kinetics of circulating immunoglobulin M in septic shock: Relationship with final outcome. *Crit Care* 17:R247, 2013. [IF: 4.950]
45. E.I. Rigopoulou, K. Zachou, N. Gatselis, G.K. Koukoulis, G.N. Dalekos. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. *Ann Hepatol* 2013 13:127-135. [IF: 1.816]
46. E.I. Rigopoulou, K. Zachou, N.K. Gatselis, G. Papadamou, G.K. Koukoulis, G.N. Dalekos. Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. *World J Hepatol* 5: 577-583, 2013. [IF: -]
47. N.K. Gatselis, K. Zachou, A. Saitis, M. Samara, G.N. Dalekos. Individualization of chronic hepatitis C treatment according to the host characteristics. *World J Gastroenterol* 20: 2839-2853, 2014. [IF: 2.787]
48. K. Zachou, S. Gambeta, N.K. Gatselis, K. Oikonomou, J. Goulis, M.N. Manoussakis, Y. Renaudineau, D.P Bogdanos, G.N. Dalekos. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. *Liver Int* 35: 660-72, 2015. [IF: 4.470]
49. G.V. Papatheodoridis, G.N. Dalekos, C. Yurdaydin, M. Buti, J. Goulis, P. Arends, V. Sypsa, S. Manolakopoulos, G. Mangia, N. Gatselis, O. Keskin, S. Savvidou, B.E. Hansen, C. Papaioannou, K. Galanis, R. Idilman, M. Colombo, R. Esteban, H.L. Janssen. P. Lampertico. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 62: 363-70, 2015. [IF: 10.590].
50. N.K. Gatselis, K. Zachou, G.K. Koukoulis, George N. Dalekos. Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics. *World J Gastroenterol* 21: 60-83, 2015. [IF: 2.787]

51. M. Kalafateli, A. Kourakli, **N.K. Gatselis**, P. Lambropoulou, K. Thomopoulos, A. Tsamandas, M. Christofidou, K. Zachou, E. Jelastopoulou, V. Nikolopoulou, A. Symeonidis, G.N. Dalekos, C. Lambropoulou-Karatza, C.K. Triantos. Efficacy of Interferon A-2b monotherapy in B-thalassemics with chronic hepatitis C. ***J Gastrointestin Liver Dis*** 24: 189-96, 2015. [IF: 1.891]
52. G.L. Norman, **N.K. Gatselis**, Z. Shums, C. Liaskos, D.P. Bogdanos, G.K. Koukoulis, G.N. Dalekos. Cartilage oligomeric matrix protein: A novel-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. ***World J Hepatol*** 7:1875-83, 2015. [IF: -]
53. A. Lyberopoulou*, G. Chachami*, **N.K. Gatselis***, E. Kyrtzopoulou*, A. Saitis, S. Gabeta, P. Eliades, E. Paraskeva, K. Zachou, G.K. Koukoulis, A. Mamalaki, G.N. Dalekos, G. Simos. Low serum hepcidin in patients with autoimmune liver diseases. ***PLoS One*** 10: e0135486, 2015 (*equally attributed). [IF: 3.057]
54. G. Papatheodoridis, G. Dalekos, V. Sypsa, C. Yurdaydin, M. Buti, J. Goulis, JL Calleja, H Chi, S. Manolakopoulos, G. Mangia, **N. Gatselis**, O. Keskin, S. Savvidou, J. de la Revilla, B.E. Hansen, I. Vlachogiannakos, K. Galanis, R. Idilman, M. Colombo, R. Esteban, H.L. Janssen, P. Lampertico. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. ***J Hepatol*** 64: 800-6, 2016. [IF: 10.590]
55. Georgitsi MD, Vitoros V, Panou C, Tsangaris I, Aimoniotou E, **Gatselis NK**, Chasou E, Kouliatsis G, Leventogiannis K, Velissaris D, Belesiotou E, Dioritou-Aggaliadou O, Giannitsioti E, Netea MG, Giamarellos-Bourboulis EJ, Giannikopoulos G, Alexiou Z, Voloudakis N, and Koutsoukou A on behalf of the Hellenic Sepsis Study Group. Individualized significance of the -251 A/T single nucleotide polymorphism of interleukin-8 in severe infections. ***Eur J Clin Microbiol Infect Dis*** 35: 563-70, 2016. [IF: 2.857]
56. Zachou K, **Gatselis NK**, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, Dalekos GN. A real-world study focused on the long-term efficacy of mycophenolate as first-line treatment of autoimmune hepatitis. ***Aliment Pharmacol Ther*** 43: 1035-47.2016. [IF: 6.320]
57. **Gatselis NK**, Dalekos GN. Molecular diagnostic testing for primary biliary cholangitis. ***Expert Rev Mol Diagn*** 2016; 16:1001-10. [IF: 3.333]
58. **Gatselis NK**, Skendros P, Ritis K, Dalekos GN. Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever. ***BMJ Case Rep*** 2016 Sep 22;2016. pii: bcr201621694. [IF: -]
59. Zachou K, Gabeta S, Shums Z, **Gatselis NK**, Koukoulis GK, Norman GL, Dalekos GN. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. ***Eur J Intern Med*** 2017; 38:83-88. [IF: 2.591]
60. Zachou K, Arvaniti P, **Gatselis NK**, Azariadis K, Papadamou G, Rigopoulou E, Dalekos GN. Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016? ***Mediterr J Hematol Infect Dis*** 2017;9: e2017003. doi: 10.4084/MJHID.2017.003. eCollection 2017. [IF: -]

61. **Gatselis NK**, Vakrakou AG, Zachou K, Androutsakos T, Azariadis K, Hatzis G, Manoussakis MN, Dalekos GN. Decreased serum DNase1-activity in patients with autoimmune liver diseases. *Autoimmunity* 2017; 50:125-132. [IF: 2.917]
62. Zachou K, Gabeta S, **Gatselis NK**, Norman GL, Dalekos GN. Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late? *Eur J Intern Med* 2017 May 11. pii: S0953-6205(17)30180-2. doi: 10.1016/j.ejim.2017.05.003. [Epub ahead of print]. [IF: 2.591]
63. **Gatselis NK**, Zachou K, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, Papadamou G, Koukoulis GK, Dalekos GN, Rigopoulou EI. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. *Eur J Intern Med.* 2017 May 20. pii: S0953-6205(17)30182-6. doi: 10.1016/j.ejim.2017.05.006. [Epub ahead of print]. [IF: 2.591]
64. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavelas S, Keskin O, **Gatselis N**, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. *Hepatology.* 2017 Jun 16. doi: 10.1002/hep.29320. [Epub ahead of print]. [IF: 13.246].
65. Polychronopoulou E, Lygoura V, **Gatselis NK**, Dalekos GN. Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. *BMJ Case Rep.* 2017 Sep 25;2017. pii: bcr-2017-220824. doi: 10.1136/bcr-2017-220824. PubMed PMID: 28951510.
66. Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, **Gatselis N**, Keskin O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. *J Hepatol* 2018;68:1129-1136.
67. Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwollegem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). *Liver Int.* 2018 May;38(5):842-850. doi: 10.1111/liv.13604. Epub 2017 Oct 26. PubMed PMID: 28963781.
68. Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, **Gatselis N**, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. *Antivir Ther.* 2018 Jul 25. doi: 10.3851/IMP3256. [Epub ahead of print] PubMed PMID: 30044765.

69. Zachou K, Arvaniti P, Azariadis K, Lygoura V, **Gatselis NK**, Lyberopoulou A, Koukoulis GK, Dalekos GN. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. *Hepato Res.* 2019 Jan;49(1):96-104. doi: 10.1111/hepr.13252. Epub 2018 Oct 18. PubMed PMID: 30248210.
70. Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, **Gatselis NK**, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HL, Hansen BE; Global PBC Study Group. Effects of Age and Sex of on Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. *Clin Gastroenterol Hepatol.* 2019 Jan 4. pii: S1542-3565(19)30001-1. doi: 10.1016/j.cgh.2018.12.028. [Epub ahead of print] PubMed PMID: 30616022.
71. Malli E, **Gatselis NK**, Dalekos GN, Petinaki E. Combination of vial culture and broad-range PCR for the diagnosis of spontaneous bacterial peritonitis: experience in a Greek tertiary care hospital. *New Microbes New Infect.* 2018 Dec 18;28:1-5.
72. Azariadis K, **Gatselis NK**, Koukoulis GK, Dalekos GN. Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. *BMJ Case Rep* 2019 Mar 20;12(3).
73. Dalekos GN, **Gatselis NK**. Variant and specific forms of Autoimmune Cholestatic Liver Diseases. *Arch Immunol Ther Exp (Warsz)* 2019; 67:197-21.
74. Dalekos GN, Gatselis NK, Zachou K. Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation? *Liver Transpl* 2019; 25:1588-1589.
75. **N.K. Gatselis**, J.C. Goet, K. Zachou¹, W.J. Lammers, H.L.A. Janssen, G. Hirschfield, C. Corpechot, K.D. Lindor, P. Invernizzi, M.J. Mayo, P.M. Battezzati, A. Floreani, A. Pares, V. Lygoura, F. Nevens, A.L. Mason, K.V. Kowdley, C.Y. Ponsioen, T. Bruns, D. Thorburn, X. Verhelst, M.H. Harms, H.R. van Buuren, B.E. Hansen, G.N. Dalekos, on behalf of the Global PBC Study Group. Factors Associated With Progression of Primary Biliary Cholangitis and Patient Outcome. *Clin Gastroenterol Hepatol Clin Gastroenterol Hepatol* 2019 Aug 13. pii: S1542-3565(19)30888-2. doi: 10.1016/j.cgh.2019.08.013. [Epub ahead of print]
76. Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, Gatselis NK, Lyberoboulou A, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulif F, Papatheodoridis GV. Predictors of HBsAg loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in non-cirrhotic HBeAg-negative chronic hepatitis B. *J Viral Hepat* 2019 Sep 28. doi: 10.1111/jvh.13211. [Epub ahead of print]
77. P. Arvaniti, K. Zachou, A. Lymperopoulou, **N.K. Gatselis**, W.H. Brooks, G.N. Dalekos, Y. Renaudineau. Epigenetic modifications in generalized autoimmune epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis. *Epigenomes* [accepted].
78. S. Georgiadou, **N.K. Gatselis**, A. Stefos, K. Zachou, K. Makaritsis, E.I. Rigopoulou, G.N. Dalekos. Efficient management of secondary haemophagocytic

lymphohistiocytosis with intravenous steroids and γ -immunoglobulin infusions. *World Clin J Cases* [accepted].

79. Murillo Perez CF, Hirschfield GM, Corpechot C, Floreani A, Mayo MJ, van der Meer A, Ponsioen CY, Lammers WL, Parés A, Invernizzi P, Carbone M, Battezzati PM, Nevens F, KV Kowdley, Thorburn D, Mason AL, Trivedi PJ, Lindor KD, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Janssen1, Bettina E. Hansen HLA, Gulamhusein A, on behalf of the GLOBAL PBC Study Group authors. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response: An analysis of the GLOBAL cohort. *Aliment Pharmacol Ther* [accepted]

• PAPERS IN GREEK MEDICAL JOURNAL

1. S. Georgiadou, K. Zachou, Ch. Liaskos, **N. Gatselis**, A. Tsikrikoni, F. Gerovasilis, M. Kardasi, E. Makri, G. Papadamou and G.N. Dalekos. Increased prevalence of occult hepatitis B virus infection in patients with chronic hepatitis C: absence of association with more severe liver disease. In: Proceedings of the 2nd Symposium on Hepatitis B and C 2003, by S.I. Hatzilyannis (Ed), Medical press P.C. Paschalidis, Athens, 2004, σ. 304-315. 2.
2. **N.K. Gatselis**, G.N. Dalekos. Autoimmune hepatitis one disease with many faces: Part I. Hellenic Journal of Medicine 101:4-30, 2014.

• CITATION INDEX & IMPACT FACTOR (until 12/10/2019)

Total Impact Factor	422.710 (avg = 6.309)
Total Impact Factor of original articles	272.958 (avg = 5.934)
Personal Impact Factor*	214.810 or 50.82% of Total Impact Factor (avg = 3.206)
Personal Impact Factor of original articles*	124.577 or 45.64% of total impact factor (avg = 2.708)
<i>*Personal Impact Factor is calculated in 100% of total number in publications as 1st or last author, 50% in publications as 2nd author, 33% in publications as 3rd author, and 25% in publications as authors in other rank)</i>	

	Google scholar	Scopus
Total citations	2278	1501
h-index	28	22
Avg of total citations (per publication)	29.974	19.750
Avg of citations of original articles	31.75	22.188

Personal total citations	1320.53 (57.97%)	838.3 (55.85%)
Avg of personal* total citations	17.375	11.328
Avg of personal* citations of original articles	16.219	11.055
<i>*Personal Citations are calculated in 100% of total number in publications as 1st or last author, 50% in publication as 2nd author, 33% in publication as 3rd author, and 25% in publication as authors in other rank.</i>		

• REFEREES

1. George N. Dalekos, M.D., Ph.D.

Professor of Medicine
 Director, Department of Medicine & Research Lab of Internal Medicine
 University of Thessaly School of Medicine
 Larissa University Hospital, Biopolis, 41110, Larissa, Greece
 Tel. +30-2413502285, Fax. +30-2413501557
 email: dalekos@med.uth.gr

2. Jean-Michel Pawlotsky, M.D., Ph.D.

Professor
 Director, French National Reference Center of Viral Hepatitis B, C, and delta,
 Chief, Department of Biology
 Head, Department of Virology, Bacteriology-Hygiene, and Mycology-Parasitology
 Head, Research Team “pathophysiology and Therapy of Chronic Viral Hepatitis”
 (INSERM U955)
 Hopital Henri Mondor
 Universite Paris Est
 51 avenue du Marechal de Lattre de Tassigny
 Tel. +33-1-49812827, Fax: +33-1-49814831
 email: jean-michel.pawlotsky@hmn.aphp.gr